XCT inhibitors and radiolabeled substrates
Glutamate analogs and radiolabeled compounds targeting the xCT antiporter inhibit cancer cell growth and offer diagnostic imaging, addressing the need for effective cancer treatment and detection.
Patent Information
- Application Number
- PCT/US2026/026883
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-08-25
- Filing Date
- 2026-05-06
- Publication Date
- 2026-11-12
AI Technical Summary
Cancer cells rely on the xCT cystine/glutamate antiporter for survival and proliferation, making it a promising therapeutic target, but existing treatments are limited.
Development of glutamate analogs and radiolabeled compounds that act as specific ligands for the xCT antiporter, functioning as PET radiotracers and therapeutic agents to inhibit xCT-mediated transport and diagnose or treat cancer.
The compounds effectively inhibit xCT activity, reducing cancer cell survival and proliferation, and provide diagnostic imaging capabilities for cancer detection.
Smart Images

Figure US2026026883_12112026_PF_FP_ABST
Abstract
Description
[0001] Attorney Docket No. 090723-1556314-25-044PCT
[0002] XCT INHIBITORS AND RADIOLABELED SUBSTRATES
[0003] CROSS-REFERENCE TO PRIORITY APPLICATIONS This application claims priority to U.S. Provisional Application No. 63 / 802,141, filed May 8, 2025, and U.S. Provisional Application No. 63 / 869,808, filed August 25, 2025, which are incorporated herein by reference in their entireties.
[0004] BACKGROUND
[0005] The cystine / glutamate antiporter xCT (SLC7A11) functions to import extracellular cystine into cells with a 1 : 1 counter-transport of glutamate. The imported cystine is then converted to cysteine, which serves as a rate-limiting precursor in glutathione synthesis and is critical to cell growth, proliferation, and metabolism. Notably, xCT is overexpressed in multiple human cancers. Many cancer cells mainly rely on the acquisition of extracellular cystine for survival and proliferation, making xCT a promising therapeutic target in cancer treatment strategies.
[0006] BRIEF SUMMARY
[0007] Disclosed herein are compounds of Formula (I):
[0008] O O
[0009]
[0010] or stereoisomers, salts, and prodrugs thereof, wherein:
[0011] n is 1, 2, 3 or 4; and
[0012] Q is -(CH2)R or -CR1R2R3, wherein,
[0013] R is a substituted aryl; and
[0014] Ri, R2, and R3 are each independently hydrogen, halogen, or halogen isotope. In certain examples, the disclosure relates to compounds of Formula (la):
[0015]
[0016] 00m(la)Attorney Docket No. 090723-1556314-25-044PCT
[0017] or stereoisomers, salts, and prodrugs thereof, wherein:
[0018] Y is a halogen or halogen isotope; and
[0019] m is 1, 2, or 3.
[0020] In certain examples, the disclosure relates to compounds of Formula (lb) or Formula (lb’):
[0021]
[0022] or stereoisomers, salts, and prodrugs thereof, wherein:
[0023] Y is a halogen or halogen isotope; and
[0024] m is 1, 2, or 3.
[0025] In certain examples, the disclosure relates to compounds of the following formula:
[0026] 0 0 O O
[0027]
[0028] ZLF2 [18F]ZLF2
[0029] or stereoisomers, salts, and prodrugs thereof.
[0030] In certain examples, the disclosure relates to compounds of Formula (II):
[0031] o
[0032]
[0033] (II)
[0034] or stereoisomers, salts, and prodrugs thereof, wherein:
[0035] X is -N- or -CH-;
[0036] Ri is selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted heteroalkenyl, substituted orAtorney Docket No. 090723-1556314-25-044PCT
[0037] unsubstituted heteroalkynyl, substituted or unsubstituted haloalkyl, substituted or unsubstituted haloalkenyl, substituted or unsubstituted haloalkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl, and substituted or unsubstituted heterocycloalkyl; and
[0038] R.2 is selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted heteroalkenyl, substituted or unsubstituted heteroalkynyl, substituted or unsubstituted haloalkyl, substituted or unsubstituted haloalkenyl, substituted or unsubstituted haloalkynyl, substituted and unsubstituted carbonyl, substituted or unsubstituted carboxyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl, and substituted or unsubstituted heterocycloalkyl,
[0039] Fi C l wherein when X
[0040]
[0041] is -CH- and Ri is ' , R2 is not
[0042] In certain examples, the disclosure relates to a composition comprising a compound of Formula (I), Formula (la), Formula (lb), Formula (lb’), or Formula (II), and a carrier.
[0043] In certain examples, the disclosure relates to a pharmaceutical formulation comprising a compound of Formula (I), Formula (la), Formula (lb), Formula (lb’), or Formula (II) or a pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable excipient or carrier.
[0044] In certain examples, the disclosure relates to a kit comprising a compound of Formula (I), Formula (la), Formula (lb), Formula (lb’), or Formula (II), a composition comprising a compound of Formula (I), Formula (la), Formula (lb), Formula (lb’), or Formula (II), and a carrier, or a pharmaceutical formulation comprising a compound of Formula (I), Formula (la), Formula (lb), Formula (lb’), or Formula (II) or a pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable excipient or carrier.
[0045] In certain examples, the disclosure relates to a method for inhibiting cystine / glutamate antiporter xCT, comprising administering to a subject an effective amount of a compound of Formula (I), Formula (la), Formula (lb), Formula (lb ’ ), or Formula (II); a composition comprising a compound of Formula (I), Formula (la), Formula (lb), Formula (lb’), or Formula (II), and a carrier; or a pharmaceutical formulation comprising a compound of Formula (I), Formula (la), Formula (lb), Formula (lb ’ ), or Formula (II) or a pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable excipient or carrier.Atorney Docket No. 090723-1556314-25-044PCT
[0046] In certain examples, the disclosure relates to a method for treating or preventing a disease or condition associated with xCT-mediated cystine-glutamate transport, the method comprising administering to a subject an effective amount of a compound of Formula (I), Formula (la), Formula (lb), Formula (lb’), or Formula (II); a composition comprising a compound of Formula (I), Formula (la), Formula (lb), Formula (lb’), or Formula (II), and a carrier; or a pharmaceutical formulation comprising a compound of Formula (I), Formula (la), Formula (lb), Formula (lb’ ), or Formula (II) or a pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable excipient or carrier.
[0047] In certain examples, the disclosure relates to a method for diagnosing and treating a disease or condition associated with xCT expression in a subject, comprising administering to a subject an effective amount of a compound of Formula (I), Formula (la), or Formula (lb), Formula (lb’), a composition comprising a compound of Formula (I), Formula (la), or Formula (lb), Formula (lb’), and a carrier, or a pharmaceutical formulation comprising a compound of Formula (I), Formula (la), or Formula (lb), Formula (lb’), or a pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable excipient or carrier.
[0048] In certain examples, the disclosure relates to a method for imaging or killing cancerous cells in a subject, comprising administering to a subject an effective amount of a radiotracer selected from Formula (la), Formula (lb), or Formula (lb ’ ):
[0049] 0 0 0 0
[0050]
[0051] or stereoisomers or salts thereof, wherein:
[0052] Y is a halogen or halogen isotope; and
[0053] m is 1, 2 or 3, wherein when m is 1, Y is halogen isotope, and when m is 2 or 3, at least one Y is halogen isotope; and
[0054] imaging the radiotracer using an imaging system.
[0055] In certain examples, the disclosure relates to a method for imaging or killing cancerous cells in a subject, comprising administering to a subject an effective amount of a radiotracer of the following formula:Attorney Docket No. 090723-1556314-25-044PCT
[0056] o o
[0057]
[0058] [18F]ZLF2
[0059] or stereoisomers or salts thereof; and
[0060] imaging the radiotracer using an imaging system.
[0061] In certain examples, the disclosure relates to compounds of Formula (Ic) or Formula (Id):
[0062]
[0063] or stereoisomers or salts thereof, wherein:
[0064] Z is a pinacol boronic ester, optionally Bpin, a boronic acid, optionally B(OH)2, or a trialkylstannyl group, optionally BusSn; and
[0065] Ri and R2 are each independently selected from hydrogen, acetyl, propanoyl, dimethylcarbamoyl, carbamoyl, carboxylic acid, ethoxy, diethylamino, acetate, and ethylthio.
[0066] In certain examples, the disclosure relates to a compound of the following formula:
[0067]
[0068] ZLFB1,Atorney Docket No. 090723-1556314-25-044PCT
[0069] HO" "OH ZLFB3,
[0070] ZLFB5,
[0071] ZLFB2,
[0072]
[0073] ZLFB4,Atorney Docket No. 090723-1556314-25-044PCT
[0074]
[0075] ZLFB6,
[0076] or stereoisomers, salts, and prodrugs thereof.
[0077] In certain examples, the disclosure relates to compounds of Formula (le) or Formula (If):
[0078]
[0079] or stereoisomers or salts thereof, wherein:
[0080] Y is a halogen or halogen isotope;
[0081] m is 1, 2 or 3, wherein when m is 1, Y is halogen isotope, and when m is 2 or 3, at least one Y is halogen isotope; and
[0082] R.4 and Rs are each independently selected from hydrogen, acetyl, propanoyl, dimethylcarbamoyl, carbamoyl, carboxylic acid, ethoxy, diethylamino, acetate, and ethylthio.
[0083] BRIEF DESCRIPTION OF THE DRAWINGS
[0084] The foregoing examples and others will be readily appreciated by the skilled artisan from the following description of illustrative examples when read together with the accompanying drawings.
[0085] FIG. 1A shows a proton [XH] NMR spectrum of compound ZLF5, in accordance with examples of the disclosure.
[0086] FIG. IB shows a carbon [13C] NMR spectrum of compound ZLF5, in accordance with examples of the disclosure.
[0087] FIG. 2A shows a proton [XH] NMR spectrum of compound ZLF6, in accordance with examples of the disclosure.Atorney Docket No. 090723-1556314-25-044PCT
[0088] FIG. 2B shows a carbon [13C] NMR spectrum of compound ZLF6, in accordance with examples of the disclosure.
[0089] FIG. 3A shows a proton [XH] NMR spectrum of compound ZLF7, in accordance with examples of the disclosure.
[0090] FIG. 3B shows a carbon [13C] NMR spectrum of compound ZLF7, in accordance with examples of the disclosure.
[0091] FIG. 4A shows a proton [XH] NMR spectrum of compound ZLFB1, in accordance with examples of the disclosure.
[0092] FIG. 4B shows a carbon [13C] NMR spectrum of compound ZLFB1, in accordance with examples of the disclosure.
[0093] FIG. 5A shows a radio-high performance liquid chromatography (HPLC) chromatogram of [18F]ZLF5, in accordance with examples of the disclosure.
[0094] FIG. 5B shows a radio-high performance liquid chromatography (HPLC) chromatogram of [18F]ZLF5, in accordance with examples of the disclosure.
[0095] FIG. 6A shows a radio-high performance liquid chromatography (HPLC) chromatogram of [131I]ZLF7, in accordance with examples of the disclosure.
[0096] FIG. 6B shows a radio-high performance liquid chromatography (HPLC) chromatogram of [131I]ZLF7, in accordance with examples of the disclosure.
[0097] FIG. 7A shows a graph of [18F]ZLF5 uptake as a percentage of total radioactivity per mg protein over a period of 2 hours in the absence and presence of cold ZLF5 (0.5 mM) in H460, H520, and HT29 cell lines, in accordance with examples of the disclosure.
[0098] FIG. 7B shows a graph of membrane-bound and internalized [131I]ZLF7 as a percentage of total radioactivity per mg protein at different incubation times in H460, A549, H520, and HT29 cell lines, in accordance with examples of the disclosure.
[0099] FIG. 8A shows a graph of [18F]ZLF5 uptake as a percentage of total radioactivity per mg protein over a period of 2 hours in the absence and presence of cold ZLF5 (0.5 mM) in H460, H520, and HT29 cell lines, in accordance with examples of the disclosure.
[0100] FIG. 8B shows a graph of membrane-bound and internalized [131I]ZLF7 as a percentage of total radioactivity per mg protein at different incubation times in H460, A549, H520, and HT29 cell lines, in accordance with examples of the disclosure.
[0101] FIG. 9 shows a graph of [18F]FSPG uptake assay and competitor compounds ZLF5, ZLF6, and ZLF7 on A549 lung cancer cells, in accordance with examples of the disclosure.Atorney Docket No. 090723-1556314-25-044PCT
[0102] FIG. 10A shows a graph of [18F]FSPG inhibition screen with 100 pM of competitor compounds ZLF1, ZLF2, ZLF3, ZLF4, ZLF5, ZLF6, and ZLF7 on H460 lung cancer cells, in accordance with examples of the disclosure.
[0103] FIG. 10B shows a graph of ICso values of [14C]cystine uptake inhibition for compounds ZLF5 (10.2 pM), ZLF6 (20.6 pM), ZLF7 (18.3 pM), and positive control FSPG (16.1 pM) on H460 lung cancer cells, in accordance with examples of the disclosure.
[0104] FIG. 11A shows a proton [' H] NMR spectrum of compound ZLG1, in accordance with examples of the disclosure.
[0105] FIG. 11B shows a carbon [13C] NMR spectrum of compound ZLG1, in accordance with examples of the disclosure.
[0106] FIG. 12A shows a proton [' H] NMR spectrum of compound ZLG11, in accordance with examples of the disclosure.
[0107] FIG. 12B shows a carbon [13C] NMR spectrum of compound ZLG11, in accordance with examples of the disclosure.
[0108] FIG. 13A shows a proton [' H] NMR spectrum of compound ZLG12, in accordance with examples of the disclosure.
[0109] FIG. 13B shows a carbon [13C] NMR spectrum of compound ZLG12, in accordance with examples of the disclosure.
[0110] FIG. 14A shows a proton [' H] NMR spectrum of compound ZLG15, in accordance with examples of the disclosure.
[0111] FIG. 14B shows a carbon [13C] NMR spectrum of compound ZLG15, in accordance with examples of the disclosure.
[0112] FIG. 15A shows a proton [' H] NMR spectrum of compound ZLGB1, in accordance with examples of the disclosure.
[0113] FIG. 15B shows a carbon [13C] NMR spectrum of compound ZLGB1, in accordance with examples of the disclosure.
[0114] FIG. 16 shows a plot of cell viability percentage for H520 cells treated with IKE (positive control), ZLA3, ZLB1, ZLB7, ZLB8, and ZLB14, in accordance with examples of the disclosure.
[0115] FIG. 17 shows a graph of [18F]FSPG uptake assay of IKE (positive control) and competitor compounds ZLA3, ZLA21, ZLB1, ZLB2, ZLB7, ZLB8, and ZLB14 on H460 cells, in accordance with examples of the disclosure.Atorney Docket No. 090723-1556314-25-044PCT
[0116] FIG. 18A shows a graph of [14C]cystine uptake inhibition screen with 10 pM of IKE (positive control) and compounds ZLG1, ZLG11, ZLG12, and ZLG15 on H460 lung cancer cells, in accordance with examples of the disclosure.
[0117] FIG. 18B shows a graph of ICso values of [14C]cystine uptake inhibition for compound ZLG12 (10.2 pM) and positive control IKE (7.5 pM) on H460 lung cancer cells, in accordance with examples of the disclosure.
[0118] FIG. 19 shows exemplary glutamate derivatives, in accordance with examples of the disclosure.
[0119] FIG. 20A shows a graph of in vitro performance of [18F]ZLF5 in lung cancer cells, in accordance with examples of the disclosure.
[0120] FIG. 20B shows a graph of in vitro performance of [18F]ZLF5 in glioblastoma cells, in accordance with examples of the disclosure.
[0121] FIG. 20C shows a graph of in vitro performance of [18F]ZLF5 in HCC cells, in accordance with examples of the disclosure.
[0122] FIG. 20D shows a graph of in vitro performance of [18F]ZLF5 in CRC cells, in accordance with examples of the disclosure.
[0123] FIG. 21 shows a graph of tracer cell uptake of [18F]ZLF5 and [18F]FSPG in H460 cells, in accordance with examples of the disclosure.
[0124] FIG. 22A shows a graph of in vitro performance of [18F]ZLF16 in lung cancer and glioblastoma cells, in accordance with examples of the disclosure.
[0125] FIG. 22B shows a graph of in vitro performance of [18F]ZLF16 in the presence of excess compounds in H460 cells, in accordance with examples of the disclosure.
[0126] FIG. 22C shows internalization ration of [18F]ZLF16 in H460 cells after 1 hour incubation, in accordance with examples of the disclosure.
[0127] FIG. 23A shows a graph of cell uptake of [131I]ZLF7 in H460 and HT29 cells, in accordance with examples of the disclosure.
[0128] FIG. 23B shows a graph of cell uptake of [131I]ZLF18 in H460 and HT29 cells, in accordance with examples of the disclosure.
[0129] FIG. 23C shows a graph of in vitro performance of [131I]ZLF7 in the presence of excess compounds in H460 cells, in accordance with examples of the disclosure.
[0130] FIG. 24A shows a graph of the biodistribution of [18F]ZLF5 in C57BL / 6 mice, in accordance with examples of the disclosure.
[0131] FIG. 24B shows a graph of the biodistribution of [18F]FSPG in C57BL / 6 mice, in accordance with examples of the disclosure.Atorney Docket No. 090723-1556314-25-044PCT
[0132] FIG. 25 shows a PET / CT image of [18F]ZLF16 in C57BL / 6 mice, in accordance with examples of the disclosure.
[0133] FIGS. 26A-26G show in vivo data of [18F]ZLF16 in the preclinical glioma rat model U87MG. FIG. 26A shows coronal BLI, MRI, and PET / MRI fusion images of rats with the orthotopic brain tumor derived from U87MG-Luc cells (top row) and without tumor (bottom row). FIG. 26B shows an axial MRI image of tumor-bearing rats. FIG. 26C shows a PET / MRI image of tumor-bearing rats. FIG. 26D is an ex vivo autoradiograph (IX) of brain sections. FIG. 26E shows hematoxylin and Eosin staining (IX) of brain sections. FIG. 26F shows immunohistochemistry staining (20X), zoom red rectangle in (E) for xCT in tumorbearing rat brain. FIG. 26G shows immunohistochemistry staining (20X), zoom red rectangle in (E) for Ki-67 in tumor-bearing rat brain.
[0134] DETAILED DESCRIPTION
[0135] Described herein are glutamate analogs and their [18F] / [123I] / [131I] / [211At]-labeled compounds, which act as specific ligands for the cystine / glutamate antiporter xCT. In certain examples, the glutamate analogs described herein are designed and synthesized for use as positron emission tomography (PET) radiotracers and therapeutic radiopharmaceuticals. Also described herein are small molecule inhibitors of the cystine / glutamate antiporter xCT and methods for their use. In certain examples, the glutamate analogs and / or the small molecule inhibitors disclosed herein are valuable for diagnosing and treating and / or preventing conditions or diseases associated with xCT expression or xCT-mediated cystine / glutamate transport, including cancer. In certain examples, methods are described for inhibiting xCT-mediated transport in a cell using the xCT glutamate analogs or the small molecule inhibitors of the present disclosure. In certain examples, methods are described for inhibiting xCT-mediated [18F]FSPG uptake in cancer cells using these glutamate analogs.
[0136] Before the present disclosure is described in greater detail, it is to be understood that this disclosure is not limited to particular examples described, and as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular examples only, and is not intended to be limiting, since the scope of the present disclosure will be limited only by the appended claims.
[0137] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Although any methods and materials similar or equivalent to thoseAtorney Docket No. 090723-1556314-25-044PCT
[0138] described herein can also be used in the practice or testing of the present disclosure, the preferred methods and materials are now described.
[0139] All publications and patents cited in this specification are herein incorporated by reference as if each individual publication or patent were specifically and individually indicated to be incorporated by reference and are incorporated herein by reference to disclose and describe the methods and / or materials in connection with which the publications are cited. The citation of any publication is for its disclosure prior to the filing date and should not be construed as an admission that the present disclosure is not entitled to antedate such publication by virtue of prior disclosure. Further, the dates of publication provided could be different from the actual publication dates that may need to be independently confirmed.
[0140] As will be apparent to those of skill in the art upon reading this disclosure, each of the individual examples described and illustrated herein has discrete components and features which may be readily separated from or combined with the features of any of the other several examples without departing from the scope or spirit of the present disclosure. Any recited method can be carried out in the order of events recited or in any other order that is logically possible.
[0141] Examples of the present disclosure will employ, unless otherwise indicated, techniques of organic chemistry, biochemistry, molecular biology, pharmacology, medicine, radiology and the like, which are within the skill of the art. Such techniques are explained fully in the literature.
[0142] It must be noted that, as used in the specification and the appended claims, the singular forms “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise. In this specification and in the claims that follow, reference will be made to a number of terms that shall be defined to have the following meanings unless a contrary intention is apparent.
[0143] Prior to describing the various examples, the following definitions are provided and should be used unless otherwise indicated. As used herein, the terms “prevent” and “preventing” include the prevention of the recurrence, spread or onset. It is not intended that the present disclosure be limited to complete prevention. In some examples, the onset is delayed, or the severity of the disease is reduced.
[0144] As used herein, the terms “treat” and “treating” are not limited to the case where the subject (e.g., patient) is cured and the disease is eradicated. Rather, examples of the present disclosure also contemplate treatment that merely reduces symptoms, and / or delays disease progression.Atorney Docket No. 090723-1556314-25-044PCT
[0145] As used herein, the term “combination with” when used to describe administration with an additional treatment means that the agent may be administered prior to, together with, or after the additional treatment, or a combination thereof. In some examples, the compounds of the present disclosure may be administered in combination with immunotherapy, DNA repair inhibition therapy, chemotherapy, or hormone therapy.
[0146] As used herein, “alkyl” means a noncyclic straight chain or branched, unsaturated or saturated hydrocarbon such as those containing from 1 to 10 carbon atoms. Representative saturated straight chain alkyls include methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, n-septyl, n-octyl, n-nonyl, and the like; while representative saturated branched alkyls include isopropyl, sec-butyl, isobutyl, tert-butyl, isopentyl, and the like. Unsaturated alkyls contain at least one double or triple bond between adjacent carbon atoms (referred to as an “alkenyl” or “alkynyl,” respectively). Representative straight chain and branched alkenyls include ethylenyl, propylenyl, 1-butenyl, 2-butenyl, isobutylenyl, 1 -pentenyl, 2-pentenyl, 3 -methyl -1-butenyl, 2-methyl-2-butenyl, 2,3- dimethyl-2-butenyl, and the like; while representative straight chain and branched alkynyls include acetylenyl, propynyl, 1-butynyl, 2-butynyl, 1-pentynyl, 2-pentynyl, 3- methyl- 1-butynyl, and the like.
[0147] As used herein, “heteroalkyl” means an alkyl which contains at least one heteroatom independently selected from nitrogen, oxygen and sulfur which may be saturated or unsaturated, and wherein the nitrogen and sulfur heteroatoms may be optionally oxidized, and the nitrogen heteroatom may be optionally quaternized. Unsaturated heteroalkyls contain at least one double or triple bond between adjacent carbon atoms (referred to as an “heteroalkenyl” or “heteroalkynyl,” respectively).
[0148] As used herein, “haloalkyl” refers to an alkyl group having one or more halogen substitutents. Representative haloalkyl groups include, but are not limited to, CF3, C2F5, CHF2, CCI3, CHCI2, C2CI5, and the like. Haloalkyls may be saturated or unsaturated.
[0149] Unsaturated haloalkyls contain at least one double or triple bond between adjacent carbon atoms (referred to as an “haloalkenyl” or “haloalkynyl,” respectively).
[0150] As used herein, “cycloalkyl” means non-aromatic mono or polycyclic alkyls.
[0151] Representative saturated cycloalkyls include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like; while unsaturated carbocycles include cyclopentenyl and cyclohexenyl, and the like.
[0152] As used herein, “heterocycloalkyl” groups are carbocycles which contain one or more (e.g., from 1 to 4) heteroatoms independently selected from nitrogen, oxygen and sulfur which may be saturated or unsaturated (but not aromatic), monocyclic or polycyclic, andAtorney Docket No. 090723-1556314-25-044PCT
[0153] wherein the nitrogen and sulfur heteroatoms may be optionally oxidized, and the nitrogen heteroatom may be optionally quaternized. Heterocycloalkyls include morpholinyl, pyrrolidinonyl, pyrrolidinyl, piperidinyl, hydantoinyl, valerolactamyl, oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydropyridinyl, tetrahydroprimidinyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, tetrahydropyrimidinyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, and the like.
[0154] As used herein, “aryl” means an aromatic carbocyclic monocyclic or polycyclic ring such as phenyl or naphthyl. Polycyclic ring systems may, but are not required to, contain one or more non-aromatic rings, as long as one of the rings is aromatic.
[0155] As used herein, “heteroaryl” refers an aromatic heterocarbocycle having one or more (e.g., 1 to 4) heteroatoms selected from nitrogen, oxygen and sulfur, and containing at least 1 carbon atom, including both mono- and polycyclic ring systems. Polycyclic ring systems may, but are not required to, contain one or more non-aromatic rings, as long as one of the rings is aromatic. Representative heteroaryls are furyl, benzofuranyl, thiophenyl, benzothiophenyl, pyrrolyl, indolyl, isoindolyl, azaindolyl, pyridyl, quinolinyl, isoquinolinyl, oxazolyl, isooxazolyl, benzoxazolyl, pyrazolyl, imidazolyl, benzimidazolyl, thiazolyl, benzothiazolyl, isothiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, cinnolinyl, phthalazinyl, and quinazolinyl. It is contemplated that the use of the term “heteroaryl” includes N-alkylated derivatives such as a l-methylimidazol-5-yl substituent.
[0156] As used herein, “heterocycle” or “heterocyclyl” refers to mono- and polycyclic ring systems having one or more (e.g., 1 to 4) heteroatoms selected from nitrogen, oxygen and sulfur, and containing at least 1 carbon atom. The mono- and polycyclic ring systems may be aromatic, non-aromatic or mixtures of aromatic and non-aromatic rings. Heterocycle includes heterocycloalkyls, heteroaryls, and the like.
[0157] As used herein, “carbonyl” refers to a functional group of atoms composed of a carbon atom double-bonded to an oxygen atom, (i.e., C=O).
[0158] As used herein, “carboxyl” refers to a functional group of atoms that includes a hydroxyl group (i.e., -OH) and a carbonyl group (i.e., C=O) where the carboxyl group is attached to the carbonyl carbon (i.e., -COOH).
[0159] As used herein, the term “substituted” refers to a molecule wherein at least one hydrogen atom is replaced with a substituent. When substituted, one or more of the groups are “substituents.” The molecule may be multiply substituted. In the case of an oxo substituent (“=O”), two hydrogen atoms are replaced. Example substituents within this context may include halogen, hydroxy, alkyl, alkoxy, nitro, cyano, oxo, carbocyclyl,Atorney Docket No. 090723-1556314-25-044PCT
[0160] carbocycloalkyl, heterocarbocyclyl, heterocarbocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, -NRaRb, -NRaC(=O)Rb, -NRaC(=O)NRaNRb, -NRaC(=O)ORb,, -NRaSChRb, -C(=O)Ra, -C(=O)ORa, -C(=O)NRaRb, -OC(=O)NRaRb, -ORa, -SRa, -SORa, -S(=O)2Ra, -OS(= O)2Raand -S(=O)2ORa. Ra and Rb in this context may be the same or different and independently hydrogen, halogen hydroxyl, alkyl, alkoxy, alkyl, amino, alkylamino, dialkylamino, carbocyclyl, carbocycloalkyl, heterocarbocyclyl, heterocarbocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl.
[0161] As used herein, “salts” refer to derivatives of the disclosed compounds where the parent compound is modified making acid or base salts thereof. Examples of salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines, alkylamines, or dialkylamines; alkali or organic salts of acidic residues such as carboxylic acids and phosphates; and the like. In a preferred example the salts are conventional nontoxic pharmaceutically acceptable salts including the quaternary ammonium salts of the parent compound formed, and non-toxic inorganic or organic acids. Preferred salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2- acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, and the like. In certain examples, the compounds herein are phosphate salts with a positive one or two metal cation such as sodium, lithium, potassium, quaternary ammonium, calcium, magnesium, or combinations thereof.
[0162] The term “subject” refers any animal, preferably a human patient, livestock, rodent, primate, monkey, or domestic pet.
[0163] The term “prodrug” refers to an agent that is converted into a biologically active form in vivo. Prodrugs are often useful because, in some situations, they may be easier to administer than the parent compound. They may, for instance, be bioavailable by oral administration whereas the parent compound is not. The prodrug may also have improved solubility in pharmaceutical compositions over the parent drug. A prodrug may be converted into the parent drug by various mechanisms, including enzymatic processes and metabolic hydrolysis.
[0164] As used herein, the term “derivative” refers to a structurally similar compound that retains sufficient functional attributes of the identified analogue. The derivative may be structurally similar because it is lacking one or more atoms, substituted, a salt, in differentAttorney Docket No. 090723-1556314-25-044PCT
[0165] hydration / oxidation states, or because one or more atoms within the molecule are switched, such as, but not limited to, replacing an oxygen atom with a sulfur or nitrogen atom or replacing an amino group with a hydroxyl group or vice versa. The derivative may be a prodrug. Derivatives may be prepared by any variety of synthetic methods or appropriate adaptations presented in synthetic or organic chemistry textbooks, such as those provide in March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, Wiley, 8th Edition (2019) Michael B. Smith or Domino Reactions in Organic Synthesis, Wiley (2006) Lutz F. Tietze hereby incorporated by reference.
[0166] COMPOUNDS
[0167] Glutamate analogs of the present disclosure
[0168] In certain examples, the disclosure relates to compounds of Formula (I):
[0169] O O
[0170] AnNH2
[0171]
[0172] 0 (I)
[0173] or stereoisomers, salts, and prodrugs thereof, wherein:
[0174] n is 1, 2, 3 or 4; and
[0175] Q is -(CH2)R or -CR1R2R3, wherein,
[0176] R is a substituted aryl; and
[0177] Ri, R2, and R3 are each independently hydrogen, halogen, or halogen isotope. In some examples, n is 2 or 3. In some examples, n is 2. In some examples, n is 3. In some examples, the substituted aryl is a substituted phenyl. In certain examples, the substituted phenyl is:
[0178]
[0179] wherein:
[0180] Y is a halogen or halogen isotope; and
[0181] m is 1, 2, or 3.
[0182] In certain examples, the substituted phenyl is:Atorney Docket No. 090723-1556314-25-044PCT
[0183]
[0184] In certain examples, Ri, R2, and R3 are each independently a halogen or a halogen isotope. In some examples, at least one of Ri, R2, and R3 is a halogen isotope. In some examples, at least one of Ri, R2, and R3 is halogen. In some examples, at least two of Ri, R2, and R3, are halogen.
[0185] In certain examples, the halogen isotope is [18F], [77Br], [76Br], [123I], [124I], [125I], [131I], or [211At]. In some examples, halogen isotope is [18F], In some examples, the halogen isotope is [77Br], In some examples, the halogen isotope is [76Br] . In some examples, the halogen isotope is [123I], In some examples, the halogen isotope is [124I], In some examples, the halogen isotope is [125I], In some examples, the halogen isotope is [131I], In some examples, the halogen isotope is [211At] .
[0186] In certain examples, the halogen is F, Cl, Br, I, or At. In some examples, the halogen is F. In some examples, the halogen is Cl. In some examples, the halogen is Br. In some examples, the halogen is I. In some examples, the halogen is At.
[0187] In certain examples, the disclosure relates to compounds of Formula (la):
[0188]
[0189] 00m(la)
[0190] or stereoisomers, salts, and prodrugs thereof, wherein:
[0191] Y is a halogen or halogen isotope; and
[0192] m is 1, 2, or 3.
[0193] In certain examples, m is 1. In certain examples, m is 2. In certain examples, m is 3. In certain examples, m is 2 or 3. In certain examples, when m is 2 or 3, one Y is halogen isotope.Attorney Docket No. 090723-1556314-25-044PCT
[0194] In certain examples, the halogen isotope is [18F], [77Br], [76Br], [123I], [124I], [125I], [131I], or [211At]. In some examples, the halogen isotope is [18F], In some examples, the halogen isotope is [77Br], In some examples, the halogen isotope is [76Br], In some examples, the halogen isotope is [123I], In some examples, the halogen isotope is [124I], In some examples, the halogen isotope is [125I], In some examples, the halogen isotope is [131I]. In some examples, the halogen isotope is [211At] .
[0195] In certain examples, the halogen is F, Cl, Br, I, or At. In some examples, the halogen is F. In some examples, the halogen is Cl. In some examples, the halogen is Br. In some examples, the halogen is I. In some examples, the halogen is At.
[0196] In certain examples, the compound is:
[0197]
[0198] ZLF7 [131I]ZLF7Attorney Docket No. 090723-1556314-25-044PCT o o
[0199] [211At]ZLF8 O O
[0200] ZLF10
[0201] ZLF14
[0202]
[0203] or stereoisomers, salts, and prodrugs thereof.
[0204] In certain examples, the compound is:Attorney Docket No. 090723-1556314-25-044PCT
[0205]
[0206] [211At]ZLF8.
[0207] or stereoisomers, salts, and prodrugs thereof.
[0208] In certain examples, the disclosure relates to compounds of Formula (lb) or Formula (lb’):
[0209]
[0210] or stereoisomers, salts, and prodrugs thereof, wherein:
[0211] Y is a halogen or halogen isotope; and
[0212] m is 1, 2, or 3.
[0213] In certain examples, the halogen isotope is [18F], [77Br], [76Br], [123I], [124I], [125I], [131I], or [211At]. In some examples, halogen isotope is [18F], In some examples, halogenAttorney Docket No. 090723-1556314-25-044PCT
[0214] isotope is [77Br], In some examples, halogen isotope is [76Br] . In some examples, the halogen isotope is [123I], In some examples, the halogen isotope is [124I], In some examples, the halogen isotope is [125I], In some examples, the halogen isotope is [131I]. In some examples, the halogen isotope is [211At] .
[0215] In certain examples, the halogen is F, Cl, Br, I, or At. In some examples, the halogen is F. In some examples, the halogen is Cl. In some examples, the halogen is Br. In some examples, the halogen is I. In some examples, the halogen is At.
[0216] In certain examples, the compound is:
[0217] ZLF16 [18F]ZLF16
[0218] 0 0 0 0 0 0
[0219]
[0220] ZLF17 ZLF18 [131I]ZLF18 or stereoisomers, salts, and prodrugs thereof.
[0221] In certain examples, the compounds of Formula (Ic) or Formula (Id) disclosed herein is:
[0222]
[0223] or stereoisomers or salts thereof, wherein:Atorney Docket No. 090723-1556314-25-044PCT
[0224] Z is a pinacol boronic ester, optionally Bpin, a boronic acid, optionally B(OH)2, or a trialkylstannyl group, optionally BusSn; and
[0225] Ri and R2 are each independently selected from hydrogen, acetyl, propanoyl, dimethylcarbamoyl, carbamoyl, carboxylic acid, ethoxy, diethylamino, acetate, and ethylthio.
[0226] In certain examples, the compound is a precursor for the synthesis of glutamate analog compounds. In certain examples, the compound is an intermediate to the synthesis of glutamate analog compounds.
[0227] In certain examples, the glutamate analog compounds are synthesized using a precursor compound of the following Formula (Ic) or Formula (Id):
[0228]
[0229] or stereoisomers or salts thereof, wherein:
[0230] Z is a pinacol boronic ester, optionally Bpin, a boronic acid, optionally B(OH)2, or a trialkylstannyl group, optionally BusSn; and
[0231] Ri and R2 are each independently selected from hydrogen, acetyl, propanoyl, dimethylcarbamoyl, carbamoyl, carboxylic acid, ethoxy, diethylamino, acetate, and ethylthio.
[0232] In certain examples, the glutamate analog compounds are synthesized using a precursor compound of the following formula:
[0233]
[0234] ZLFB1,Atorney Docket No. 090723-1556314-25-044PCT
[0235] HO" "OH ZLFB3,
[0236] ZLFB5,
[0237] ZLFB2,
[0238]
[0239] ZLFB4,Attorney Docket No. 090723-1556314-25-044PCT
[0240]
[0241] ZLFB6,
[0242] or stereoisomers and salts thereof.
[0243] In certain examples, the compound is:
[0244] O O O O
[0245]
[0246] ZLF2 [18F]ZLF2 or stereoisomers, salts, and prodrugs thereof.
[0247] In certain examples, the compound is:
[0248] O O
[0249]
[0250] ZLF2
[0251] or stereoisomers, salts, and prodrugs thereof.
[0252] In certain examples, the compound is:
[0253] O O
[0254]
[0255] [18F]ZLF2
[0256] or stereoisomers, salts, and prodrugs thereof.
[0257] In certain examples, the disclosure relates to compounds of Formula (le) or Formula (If):Atorney Docket No. 090723-1556314-25-044PCT
[0258]
[0259] or stereoisomers or salts thereof, wherein:
[0260] Y is a halogen or halogen isotope;
[0261] m is 1, 2 or 3, wherein when m is 1, Y is halogen isotope, and when m is 2 or 3, at least one Y is halogen isotope; and
[0262] R.4 and Rs are each independently selected from hydrogen, acetyl, propanoyl, dimethylcarbamoyl, carbamoyl, carboxylic acid, ethoxy, diethylamino, acetate, and ethylthio.
[0263] Small Molecule Inhibitors of Cystine / Glutamate Antiporter xCT
[0264] In certain examples, the disclosure relates to compounds of Formula (II):
[0265] o
[0266] A
[0267]
[0268] R2 (II)
[0269] or stereoisomers, salts, and prodrugs thereof, wherein:
[0270] X is -N- or -CH-;
[0271] Ri is selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted heteroalkenyl, substituted or unsubstituted heteroalkynyl, substituted or unsubstituted haloalkyl, substituted or unsubstituted haloalkenyl, substituted or unsubstituted haloalkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl, and substituted or unsubstituted heterocycloalkyl; and
[0272] R2 is selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted heteroalkenyl, substituted or unsubstituted heteroalkynyl, substituted or unsubstituted haloalkyl, substituted orAttorney Docket No. 090723-1556314-25-044PCT
[0273] unsubstituted haloalkenyl, substituted or unsubstituted haloalkynyl, substituted and unsubstituted carbonyl, substituted or unsubstituted carboxyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl, and substituted or unsubstituted heterocycloalkyl,
[0274] wherein when X
[0275]
[0276] is -CH- and Ri is
[0277] In certain examples, X is -N-. In certain examples, X is -CH-.
[0278] In certain examples, R
[0279]
[0280] i is or 4 and Rr is halogen or bis(pinacolato)diboron. In certain examples, when Ri is
[0281] n is 0. In certain
[0282] e
[0283]
[0284] xamples, when Ri is In certain examples, when n is 1, Rr is halogen. In certain examples, when n is 1, Rr is bis(pinacolato)diboron.
[0285] In certain examples, R2 is
[0286]
[0287] In certain examples, R2 is
[0288]
[0289] In certain examples, R2 is In certain examples, R2 is
[0290]
[0291] In certain examples, R2 is In certain examples, R2 isAttorney Docket No. 090723-1556314-25-044PCT
[0292] "j" — ’ , • ‘'J In certain examples, R2 is In certain examples, R2 is
[0293]
[0294] In certain examples, the compound is:
[0295]
[0296] ZLB8Atorney Docket No. 090723-1556314-25-044PCT
[0297]
[0298] ZLB8Atorney Docket No. 090723-1556314-25-044PCT ZLB14
[0299] ZLG1 ZLG11
[0300]
[0301] ZLG15Attorney Docket No. 090723-1556314-25-044PCT
[0302]
[0303] or stereoisomers, salts, and prodrugs thereof.
[0304] In certain examples, the compound is:
[0305]
[0306] or stereoisomers, salts, and prodrugs thereof.
[0307] In certain examples, the compound is:
[0308]
[0309] ZLG12
[0310] or stereoisomers, salts, and prodrugs thereof.Attorney Docket No. 090723-1556314-25-044PCT
[0311] Glutamate derivatives of the present disclosure
[0312] Also described herein are compounds that are glutamate derivatives. In certain examples, the glutamate derivatives are:
[0313] O
[0314] MDA1101 O OH
[0315]
[0316] MDA1104Attorney Docket No. 090723-1556314-25-044PCT
[0317] o
[0318] MDA1105 MDA1106
[0319] MDA1206
[0320] MDA1208
[0321]
[0322] ZLF21 or stereoisomers, salts, and prodrugs thereof. In some cases, the compound is not ZLF21. Optionally, the glutamate derivatives described herein are the isomers as shown in Fig. 19.
[0323] COMPOSITIONS
[0324] In certain examples, the disclosure relates to a composition including a compound of any one of Formula (I), Formula (la), Formula (lb), Formula (lb’), Formula (Ic), Formula (Id), Formula (le), Formula (If), or Formula (II), and a carrier. In certain examples, the disclosure relates to a composition including a compound of Formula (I) and a carrier. In certain examples, the disclosure relates to a composition including a compound of Formula (la) and a carrier. In certain examples, the disclosure relates to a composition including aAtorney Docket No. 090723-1556314-25-044PCT
[0325] compound of Formula (lb) and a carrier. In certain examples, the disclosure relates to a composition including a compound of Formula (lb’) and a carrier. In certain examples, the disclosure relates to a composition including a compound of Formula (Ic) and a carrier. In certain examples, the disclosure relates to a composition including a compound of Formula (Id) and a carrier. In certain examples, the disclosure relates to a composition including a compound of Formula (le) and a carrier. In certain examples, the disclosure relates to a composition including a compound of Formula (If) and a carrier. In certain examples, the disclosure relates to a composition including a compound of Formula (II) and a carrier. As used herein, a “carrier” is a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting the subject chemical from one organ, or portion of the body, to another organ, or portion of the body. Representative and suitable carriers are described, for example, in handbooks, such as Remington's Pharmaceutical Sciences:
[0326] Remington, J. P. (2021). Remington: the science and practice of pharmacy (A. Adejare, Ed.; 23rd edition; Elsevier).
[0327] In certain examples, the disclosure relates to a composition including compounds as shown below:
[0328]
[0329] ZLF7Atorney Docket No. 090723-1556314-25-044PCT
[0330]
[0331] Attorney Docket No. 090723-1556314-25-044PCT
[0332] o o
[0333] ZLF18
[0334] O O
[0335]
[0336] [131I]ZLF18 or stereoisomers, salts, and prodrugs thereof.
[0337] In certain examples, the disclosure relates to a composition including a compound as shown below:
[0338] O O
[0339]
[0340] [18F]ZLF2 or stereoisomers, salts, and prodrugs thereof.
[0341] In certain examples, the disclosure relates to a composition including a compound as shown below:Atorney Docket No. 090723-1556314-25-044PCT
[0342] ZLB7
[0343] ZLA3
[0344] ZLA21
[0345]
[0346] Atorney Docket No. 090723-1556314-25-044PCT
[0347] ZLB14
[0348]
[0349] ZLG1Attorney Docket No. 090723-1556314-25-044PCT
[0350]
[0351] or stereoisomers, salts, and prodrugs thereof.
[0352] PHARMACEUTICAL FORMULATIONS
[0353] In certain examples, the disclosure relates to a pharmaceutical formulation including a compound of any one of Formula (I), Formula (la), Formula (lb), Formula (lb’), Formula (Ic), Formula (Id), Formula (le), Formula (If),orFormula (II), or a pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable excipient or carrier. InAtorney Docket No. 090723-1556314-25-044PCT
[0354] certain examples, the disclosure relates to a pharmaceutical formulation including a compound of Formula (I) or a pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable excipient or carrier. In certain examples, the disclosure relates to a pharmaceutical formulation including a compound of Formula (la) or a pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable excipient or carrier. In certain examples, the disclosure relates to a pharmaceutical formulation including a compound of Formula (lb) or a pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable excipient or carrier. In certain examples, the disclosure relates to a pharmaceutical formulation including a compound of Formula (lb’) or a pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable excipient or carrier. In certain examples, the disclosure relates to a pharmaceutical formulation including a compound of Formula (Ic) or a pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable excipient or carrier. In certain examples, the disclosure relates to a pharmaceutical formulation including a compound of Formula (Id) or a pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable excipient or carrier. In certain examples, the disclosure relates to a pharmaceutical formulation including a compound of Formula (le) or a pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable excipient or carrier. In certain examples, the disclosure relates to a pharmaceutical formulation including a compound of Formula (If) or a pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable excipient or carrier. In certain examples, the disclosure relates to a pharmaceutical formulation including a compound of Formula (II) or a pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable excipient or carrier.
[0355] In certain examples, the disclosure relates to a pharmaceutical formulation including compounds as shown below:
[0356] O O HO OH
[0357]
[0358] ZLF5Atorney Docket No. 090723-1556314-25-044PCT ZLF7
[0359]
[0360] Attorney Docket No. 090723-1556314-25-044PCT
[0361] ZLF16
[0362]
[0363] [18F]ZLF16 [131I]ZLF18
[0364] or stereoisomers, salts, and prodrugs thereof.
[0365] In certain examples, the disclosure relates to a pharmaceutical formulation including a compound as shown below:
[0366]
[0367] ZLF2 [18F]ZLF2
[0368] or stereoisomers, salts, and prodrugs thereof.Attorney Docket No. 090723-1556314-25-044PCT
[0369] In certain examples, the disclosure relates to a pharmaceutical formulation including a compound as shown below:
[0370] ZLB8
[0371]
[0372] ZLA22Atorney Docket No. 090723-1556314-25-044PCT
[0373] ZLB14
[0374]
[0375] ZLG1Attorney Docket No. 090723-1556314-25-044PCT
[0376]
[0377] or stereoisomers, salts, and prodrugs thereof.
[0378] Pharmaceutical formulations for use in the present disclosure typically include an effective amount of a compound as disclosed herein and a suitable pharmaceutical acceptable carrier. The preparations may be prepared in a manner known per se, which usually involves mixing at least one compound according to the disclosure with a pharmaceutically acceptable carrier, and, if desired, in combination with other pharmaceutically active compounds, when necessary under aseptic conditions. In certain examples, the pharmaceutical formulation mayAtorney Docket No. 090723-1556314-25-044PCT
[0379] include one or more pharmaceutically acceptable carriers. Representative and suitable carriers are described, for example, in handbooks, such as Remington's Pharmaceutical Sciences: Remington, J. P. (2021). Remington: the science and practice of pharmacy (A. Adejare, Ed.; 23rd edition; Elsevier).
[0380] Generally, for pharmaceutical use, the compounds may be formulated as a pharmaceutical formulation including at least one compound and at least one pharmaceutically acceptable carrier, diluent or excipient and / or adjuvant, and optionally one or more further pharmaceutically active compounds.
[0381] The pharmaceutical formulations of the disclosure are preferably in a unit dosage form, and may be suitably packaged, for example in a box, blister, vial, bottle, sachet, ampoule or in any other suitable single-dose or multi-dose holder or container (which may be properly labeled); optionally with one or more leaflets containing product information and / or instructions for use. Generally, such unit dosages will contain between 10 pg and 500 mg, and preferably between 25 pg and 125 mg, of the at least one compound of the disclosure, e.g., about 25, 50, 75, 100, 200, or 300 pg or about 25, 50, 75, 100, 200 or 300 mg per unit dosage.
[0382] The compounds can be administered by intravenous injection, intraperitoneal injection, or subcutaneous injection. The compound will generally be administered in an “effective amount”, by which is meant any amount of a compound that, upon suitable administration, is sufficient to achieve the desired therapeutic effect in the subject to which it is administered. In certain examples, dosage concentrations up to several hundred milligrams per kilogram may be used. Usually, depending on the condition to be prevented or treated, such an effective amount will usually be between 0.01 to 1000 mg per kilogram body weight of the patient per day, more often between 0.1 and 500 mg, such as between 1 and 250 mg, for example about 5, 10, 20, 50, 100, 150, 200 or 250 mg, per kilogram body weight of the patient per day, which may be administered as a single daily dose, divided over one or more daily doses. The amount(s) to be administered and the further treatment regimen may be determined by the treating clinician, depending on factors such as the age, gender and general condition of the patient and the nature and severity of the disease / symptoms to be treated. Representative and suitable amounts to be administered are described, for example, in handbooks, such as Remington's Pharmaceutical Sciences: Remington, J. P.
[0383] (2021). Remington: the science and practice of pharmacy (A. Adejare, Ed.; 23rd edition; Elsevier).Atorney Docket No. 090723-1556314-25-044PCT
[0384] In certain examples, dosages for imaging or therapy may range from at least 5 to at last 150 millicurie (mCi). In certain examples, dosages for imaging may be at least 5, at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least, 55, at least 60, at least 65, at least 70, at least 75, at least 80, at least 85, at least 90, at least 95, at least 100, at least 105, at least 110, at least 115, at least 120, at least 125, at least 130, at least 135, at least 140, at least 145, or at least 150 mCi.
[0385] Compounds of the present disclosure can be incorporated in a pharmaceutical formulation in a concentration from 0.5 pM to 1000 mM, wherein said formulation has a pH from 4.5 to 8.0. The formulation may further include a buffer system, preservative(s), tonicity agent(s), chelating agents(s), stabilizers and surfactants. In certain examples, the pharmaceutical formulation is an aqueous formulation (i.e., a formulation including water). Such formulation is typically a solution or a suspension. In a further embodiment, the pharmaceutical formulation is an aqueous solution. The term “aqueous formulation” is defined as a formulation including at least 50% w / w water. Likewise, the term “aqueous solution” is defined as a solution including at least 50% w / w water, and the term “aqueous suspension” is defined as a suspension including at least 50% w / w water.
[0386] In certain examples, the pharmaceutical formulation is a freeze-dried formulation, wherein the physician or the patient adds solvents and / or diluents prior to use.
[0387] In certain examples, the pH of the formulation is in the range selected from the list consisting of from about 4.0 to about 8.5, about 4.5 to 8.0, about 5.0 to about 8.0, and about 5.5 to about 7.5. In certain examples the pH of the formulation is 4.5, 5.0, 6.0, 6.5, 7.0, 7.5, or 8.0.
[0388] In certain examples, the buffer is selected from the group consisting of sodium acetate, sodium carbonate, citrate, glycylglycine, histidine, glycine, lysine, arginine, sodium dihydrogen phosphate, di sodium hydrogen phosphate, sodium phosphate, and tris(hydroxymethyl)-aminomethane, bicine, tricine, malic acid, succinate, maleic acid, fumaric acid, tartaric acid, aspartic acid or mixtures thereof. Each one of these specific buffers constitutes an alternative embodiment of the disclosure.
[0389] In certain examples, the pharmaceutical formulation further includes a pharmaceutically acceptable preservative. In certain examples, the formulation further includes an isotonic agent. In certain examples, the formulation also includes a chelating agent. In certain examples, the formulation further includes a stabilizer. In certain examples, the formulation further includes a surfactant. Representative and suitable surfactants are described, for example, in handbooks, such as Remington's Pharmaceutical Sciences:Atorney Docket No. 090723-1556314-25-044PCT
[0390] Remington, J. P. (2021). Remington: the science and practice of pharmacy (A. Adejare, Ed.; 23rd edition; Elsevier).
[0391] It is possible that other ingredients may be present in the pharmaceutical formulation of the present disclosure. Such additional ingredients may include wetting agents, emulsifiers, antioxidants, bulking agents, tonicity modifiers, chelating agents, metal ions, oleaginous vehicles, proteins (e.g., human serum albumin, gelatine or proteins) and a zwitterion (e.g., an amino acid such as betaine, taurine, arginine, glycine, lysine and histidine). Such additional ingredients, of course, should not adversely affect the overall stability of the pharmaceutical formulation of the present disclosure.
[0392] KITS
[0393] Also provided herein are kits including a compound of any one of Formula (I), Formula (la), Formula (lb), Formula (lb’), Formula (Ic), Formula (Id), Formula (le), Formula (If), or Formula (II). In certain examples, the kits include a compound of Formula (I). In certain examples, the kits include a compound of Formula (la). In certain examples, the kits include a compound of Formula (lb). In certain examples, the kits include a compound of Formula (lb’). In certain examples, the kits include a compound of Formula (Ic). In certain examples, the kits include a compound of Formula (Id). In certain examples, the kits include a compound of Formula (le). In certain examples, the kits include a compound of Formula (If). In certain examples, the kits include a compound of Formula (II).
[0394] In certain examples, the kits disclosed herein include a composition including a compound of any one of Formula (I), Formula (la), Formula (lb), Formula (lb’), Formula (Ic), Formula (Id), Formula (le), Formula (If), or Formula (II), and a carrier. In certain examples, the kits include a composition including a compound of Formula (I) and a carrier. In certain examples, the kits include a composition including a compound of Formula (la) and a carrier. In certain examples, the kits include a composition including a compound of Formula (lb) and a carrier. In certain examples, the kits include a composition including a compound of Formula (lb’) and a carrier. In certain examples, the kits include a composition including a compound of Formula (Ic) and a carrier. In certain examples, the kits include a composition including a compound of Formula (Id) and a carrier. In certain examples, the kits include a composition including a compound of Formula (le) and a carrier. In certain examples, the kits include a composition including a compound of Formula (If) and a carrier. In certain examples, the kits include a composition including a compound of Formula (II) and a carrier.Atorney Docket No. 090723-1556314-25-044PCT
[0395] In certain examples, the kits include a pharmaceutical formulation including a compound of any one of Formula (I), Formula (la), Formula (lb), Formula (lb’), Formula (Ic), Formula (Id), Formula (le), Formula (If), or Formula (II), or a pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable excipient or carrier. In certain examples, the kits include a pharmaceutical formulation including a compound of Formula (I) or a pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable excipient or carrier. In certain examples, the kits include a pharmaceutical formulation including a compound of Formula (la) or a pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable excipient or carrier. In certain examples, the kits include a pharmaceutical formulation including a compound of Formula (lb) or a pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable excipient or carrier. In certain examples, the kits include a pharmaceutical formulation including a compound of Formula (lb’) or a pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable excipient or carrier. In certain examples, the kits include a pharmaceutical formulation including a compound of Formula (Ic) or a pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable excipient or carrier. In certain examples, the kits include a pharmaceutical formulation including a compound of Formula (Id) or a pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable excipient or carrier. In certain examples, the kits include a pharmaceutical formulation including a compound of Formula (le) or a pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable excipient or carrier. In certain examples, the kits include a pharmaceutical formulation including a compound of Formula (If) or a pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable excipient or carrier. In certain examples, the kits include a pharmaceutical formulation including a compound of Formula (II) or a pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable excipient or carrier.
[0396] METHODS OF USE
[0397] In certain examples, the disclosure relates to methods for inhibiting cystine / glutamate antiporter xCT, including administering an effective amount of a compound of any one of Formula (I), Formula (la), Formula (lb), Formula (lb’), Formula (Ic), Formula (Id), Formula (le), Formula (If), or Formula (II), in accordance with the compounds of this disclosure. In certain examples, the disclosure relates to methods for inhibiting cystine / glutamate antiporterAtorney Docket No. 090723-1556314-25-044PCT
[0398] xCT, including administering an effective amount of a compound of Formula (I) in accordance with the compounds of this disclosure. In certain examples, the disclosure relates to methods for inhibiting cystine / glutamate antiporter xCT, including administering an effective amount of a compound of Formula (la) in accordance with the compounds of this disclosure. In certain examples, the disclosure relates to methods for inhibiting cystine / glutamate antiporter xCT, including administering an effective amount of a compound of Formula (lb) in accordance with the compounds of this disclosure. In certain examples, the disclosure relates to methods for inhibiting cystine / glutamate antiporter xCT, including administering an effective amount of a compound of Formula (lb’) in accordance with the compounds of this disclosure. In certain examples, the disclosure relates to methods for inhibiting cystine / glutamate antiporter xCT, including administering an effective amount of a compound of Formula (Ic) in accordance with the compounds of this disclosure. In certain examples, the disclosure relates to methods for inhibiting cystine / glutamate antiporter xCT, including administering an effective amount of a compound of Formula (Id) in accordance with the compounds of this disclosure. In certain examples, the disclosure relates to methods for inhibiting cystine / glutamate antiporter xCT, including administering an effective amount of a compound of Formula (le) in accordance with the compounds of this disclosure. In certain examples, the disclosure relates to methods for inhibiting cystine / glutamate antiporter xCT, including administering an effective amount of a compound of Formula (If) in accordance with the compounds of this disclosure. In certain examples, the disclosure relates to methods for inhibiting cystine / glutamate antiporter xCT, including administering an effective amount of a compound of Formula (II) in accordance with the compounds of this disclosure.
[0399] In certain examples, the disclosure relates to methods for inhibiting cystine / glutamate antiporter xCT, including administering an effective amount of a composition including a compound of any one of Formula (I), Formula (la), Formula (lb), Formula (lb’), Formula (Ic), Formula (Id), Formula (le), Formula (If), or Formula (II), and a carrier. In certain examples, the disclosure relates to methods for inhibiting cystine / glutamate antiporter xCT, including administering an effective amount of a composition including a compound of Formula (I) and a carrier. In certain examples, the disclosure relates to methods for inhibiting cystine / glutamate antiporter xCT, including administering an effective amount of a composition including a compound of Formula (la) and a carrier. In certain examples, the disclosure relates to methods for inhibiting cystine / glutamate antiporter xCT, including administering an effective amount of a composition including a compound of Formula (lb)Atorney Docket No. 090723-1556314-25-044PCT
[0400] and a carrier. In certain examples, the disclosure relates to methods for inhibiting cystine / glutamate antiporter xCT, including administering an effective amount of a composition including a compound of Formula (lb’) and a carrier. In certain examples, the disclosure relates to methods for inhibiting cystine / glutamate antiporter xCT, including administering an effective amount of a composition including a compound of Formula (Ic) and a carrier. In certain examples, the disclosure relates to methods for inhibiting cystine / glutamate antiporter xCT, including administering an effective amount of a composition including a compound of Formula (Id) and a carrier. In certain examples, the disclosure relates to methods for inhibiting cystine / glutamate antiporter xCT, including administering an effective amount of a composition including a compound of Formula (le) and a carrier. In certain examples, the disclosure relates to methods for inhibiting cystine / glutamate antiporter xCT, including administering an effective amount of a composition including a compound of Formula (If) and a carrier. In certain examples, the disclosure relates to methods for inhibiting cystine / glutamate antiporter xCT, including administering an effective amount of a composition including a compound of Formula (II) and a carrier.
[0401] In certain examples, the disclosure relates to methods for inhibiting cystine / glutamate antiporter xCT, including administering an effective amount of a pharmaceutical formulation including a compound of any one of Formula (I), Formula (la), Formula (lb), Formula (lb’), Formula (Ic), Formula (Id), Formula (le), Formula (If), or Formula (II), or a pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable excipient or carrier. In certain examples, the disclosure relates to methods for inhibiting cystine / glutamate antiporter xCT, including administering an effective amount of a pharmaceutical formulation including a compound of Formula (I) or a pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable excipient or carrier. In certain examples, the disclosure relates to methods for inhibiting cystine / glutamate antiporter xCT, including administering an effective amount of a pharmaceutical formulation including a compound of Formula (la) or a pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable excipient or carrier. In certain examples, the disclosure relates to methods for inhibiting cystine / glutamate antiporter xCT, including administering an effective amount of a pharmaceutical formulation including a compound of Formula (lb) or a pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable excipient or carrier. In certain examples, the disclosure relates to methods for inhibiting cystine / glutamate antiporter xCT, including administering an effective amount of a pharmaceutical formulation includingAtorney Docket No. 090723-1556314-25-044PCT
[0402] a compound of Formula (lb’) or a pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable excipient or carrier. In certain examples, the disclosure relates to methods for inhibiting cystine / glutamate antiporter xCT, including administering an effective amount of a pharmaceutical formulation including a compound of Formula (Ic) or a pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable excipient or carrier. In certain examples, the disclosure relates to methods for inhibiting cystine / glutamate antiporter xCT, including administering an effective amount of a pharmaceutical formulation including a compound of Formula (Id) or a pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable excipient or carrier. In certain examples, the disclosure relates to methods for inhibiting cystine / glutamate antiporter xCT, including administering an effective amount of a pharmaceutical formulation including a compound of Formula (le) or a pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable excipient or carrier. In certain examples, the disclosure relates to methods for inhibiting cystine / glutamate antiporter xCT, including administering an effective amount of a pharmaceutical formulation including a compound of Formula (If) or a pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable excipient or carrier. In certain examples, the disclosure relates to methods for inhibiting cystine / glutamate antiporter xCT, including administering an effective amount of a pharmaceutical formulation including a compound of Formula (II) or a pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable excipient or carrier.
[0403] In certain examples, the compound of the present disclosure inhibits xCT-mediated cystine / glutamate transport in a cell.
[0404] In certain examples, the disclosure relates to methods for treating or preventing a disease or condition associated with xCT-mediated cystine-glutamate transport, the method including administering an effective amount of a compound of any one of Formula (I), Formula (la), Formula (lb), Formula (lb’), Formula (Ic), Formula (Id), Formula (le), Formula (If), or Formula (II), in accordance with the compounds of this disclosure. In certain examples, the disclosure relates to methods for treating or preventing a disease or condition associated with xCT-mediated cystine-glutamate transport, the method including administering an effective amount of a compound of Formula (I) in accordance with the compounds of this disclosure. In certain examples, the disclosure relates to methods for treating or preventing a disease or condition associated with xCT-mediated cystine-glutamate transport, the method including administering an effective amount of a compound of Formula (la) in accordance with the compounds of this disclosure. In certain examples, the disclosureAtorney Docket No. 090723-1556314-25-044PCT
[0405] relates to methods for treating or preventing a disease or condition associated with xCT-mediated cystine-glutamate transport, the method including administering an effective amount of a compound of Formula (lb) in accordance with the compounds of this disclosure. In certain examples, the disclosure relates to methods for treating or preventing a disease or condition associated with xCT-mediated cystine-glutamate transport, the method including administering an effective amount of a compound of Formula (lb’) in accordance with the compounds of this disclosure. In certain examples, the disclosure relates to methods for treating or preventing a disease or condition associated with xCT-mediated cystine-glutamate transport, the method including administering an effective amount of a compound of Formula (Ic) in accordance with the compounds of this disclosure. In certain examples, the disclosure relates to methods for treating or preventing a disease or condition associated with xCT-mediated cystine-glutamate transport, the method including administering an effective amount of a compound of Formula (Id) in accordance with the compounds of this disclosure. In certain examples, the disclosure relates to methods for treating or preventing a disease or condition associated with xCT-mediated cystine-glutamate transport, the method including administering an effective amount of a compound of Formula (le) in accordance with the compounds of this disclosure. In certain examples, the disclosure relates to methods for treating or preventing a disease or condition associated with xCT-mediated cystine-glutamate transport, the method including administering an effective amount of a compound of Formula (If) in accordance with the compounds of this disclosure. In certain examples, the disclosure relates to methods for treating or preventing a disease or condition associated with xCT-mediated cystine-glutamate transport, the method including administering an effective amount of a compound of Formula (II) in accordance with the compounds of this disclosure.
[0406] In certain examples, the disclosure relates to methods for treating or preventing a disease or condition associated with xCT-mediated cystine-glutamate transport, the method including administering an effective amount of a composition including a compound of any one of Formula (I), Formula (la), Formula (lb), Formula (lb’), Formula (Ic), Formula (Id), Formula (le), Formula (If), or Formula (II), and a carrier. In certain examples, the disclosure relates to methods for treating or preventing a disease or condition associated with xCT-mediated cystine-glutamate transport, the method including administering an effective amount of a composition including a compound of Formula (I) and a carrier. In certain examples, the disclosure relates to methods for treating or preventing a disease or condition associated with xCT-mediated cystine-glutamate transport, the method including administering an effective amount of a composition including a compound of Formula (la)Atorney Docket No. 090723-1556314-25-044PCT
[0407] and a carrier. In certain examples, the disclosure relates to methods for treating or preventing a disease or condition associated with xCT-mediated cystine-glutamate transport, the method including administering an effective amount of a composition including a compound of Formula (lb) and a carrier. In certain examples, the disclosure relates to methods for treating or preventing a disease or condition associated with xCT-mediated cystine-glutamate transport, the method including administering an effective amount of a composition including a compound of Formula (lb’) and a carrier. In certain examples, the disclosure relates to methods for treating or preventing a disease or condition associated with xCT-mediated cystine-glutamate transport, the method including administering an effective amount of a composition including a compound of Formula (Ic) and a carrier. In certain examples, the disclosure relates to methods for treating or preventing a disease or condition associated with xCT-mediated cystine-glutamate transport, the method including administering an effective amount of a composition including a compound of Formula (Id) and a carrier. In certain examples, the disclosure relates to methods for treating or preventing a disease or condition associated with xCT-mediated cystine-glutamate transport, the method including administering an effective amount of a composition including a compound of Formula (le) and a carrier. In certain examples, the disclosure relates to methods for treating or preventing a disease or condition associated with xCT-mediated cystine-glutamate transport, the method including administering an effective amount of a composition including a compound of Formula (If) and a carrier. In certain examples, the disclosure relates to methods for treating or preventing a disease or condition associated with xCT-mediated cystine-glutamate transport, the method including administering an effective amount of a composition including a compound of Formula (II) and a carrier.
[0408] In certain examples, the disclosure relates to methods for treating or preventing a disease or condition associated with xCT-mediated cystine-glutamate transport, the method including administering an effective amount of a pharmaceutical formulation including a compound of any one of Formula (I), Formula (la), Formula (lb), Formula (lb’), Formula (Ic), Formula (Id), Formula (le), Formula (If), or Formula (II), or a pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable excipient or carrier. In certain examples, the disclosure relates to methods for treating or preventing a disease or condition associated with xCT-mediated cystine-glutamate transport, the method including administering an effective amount of a pharmaceutical formulation including a compound of Formula (I) or a pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable excipient or carrier. In certain examples, the disclosure relates to methods forAtorney Docket No. 090723-1556314-25-044PCT
[0409] treating or preventing a disease or condition associated with xCT-mediated cystine-glutamate transport, the method including administering an effective amount of a pharmaceutical formulation including a compound of Formula (la) or a pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable excipient or carrier. In certain examples, the disclosure relates to methods for treating or preventing a disease or condition associated with xCT-mediated cystine-glutamate transport, the method including administering an effective amount of a pharmaceutical formulation including a compound of Formula (lb) or a pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable excipient or carrier. In certain examples, the disclosure relates to methods for treating or preventing a disease or condition associated with xCT-mediated cystine-glutamate transport, the method including administering an effective amount of a pharmaceutical formulation including a compound of Formula (lb’) or a pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable excipient or carrier. In certain examples, the disclosure relates to methods for treating or preventing a disease or condition associated with xCT-mediated cystine-glutamate transport, the method including administering an effective amount of a pharmaceutical formulation including a compound of Formula (Ic) or a pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable excipient or carrier. In certain examples, the disclosure relates to methods for treating or preventing a disease or condition associated with xCT-mediated cystine-glutamate transport, the method including administering an effective amount of a pharmaceutical formulation including a compound of Formula (Id) or a pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable excipient or carrier. In certain examples, the disclosure relates to methods for treating or preventing a disease or condition associated with xCT-mediated cystine-glutamate transport, the method including administering an effective amount of a pharmaceutical formulation including a compound of Formula (le) or a pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable excipient or carrier. In certain examples, the disclosure relates to methods for treating or preventing a disease or condition associated with xCT-mediated cystine-glutamate transport, the method including administering an effective amount of a pharmaceutical formulation including a compound of Formula (If) or a pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable excipient or carrier. In certain examples, the disclosure relates to methods for treating or preventing a disease or condition associated with xCT-mediated cystine-glutamate transport, the method including administering an effective amount of a pharmaceutical formulation including a compound of Formula (II) or aAtorney Docket No. 090723-1556314-25-044PCT
[0410] pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable excipient or carrier.
[0411] In certain examples, the disease or condition associated with xCT-mediated cystineglutamate transport is cancer. In certain examples, the cancer is liver cancer, lung cancer, colorectal cancer, oral squamous cell carcinoma, bladder cancer, blood cancer, bone marrow cancer, brain cancer, breast cancer, bronchus cancer, cervical cancer, chondrosarcoma, endometrial cancer, gastrointestinal cancer, gastric cancer, esophageal cancer, genitourinary cancer, head and neck cancer, leukemia, lymphoma, ovarian cancer, pancreatic cancer, prostate cancer, renal cancer, skin cancer, testicular cancer, thyroid cancer, cholangiocarcinoma, or uterine cancer.
[0412] In certain examples, the disease or condition associated with xCT-mediated cystineglutamate transport is ferroptosis. In certain examples, the disease or condition is a neurodegenerative disorder. In some examples, the disease or condition is Alzheimer’s Disease (AD), Parkinson’s Disease (PD), or schizophrenia. In certain examples, the disease or condition is amyotrophic lateral sclerosis. In certain examples, the disease or condition is oxidative stress. In certain examples, the disease or condition is a cardiovascular disease. In some examples, the disease or condition is ischemia-reperfusion injury or atherosclerosis, or heart failure. In certain examples, the disease or condition is an inflammatory disease. In some examples, the disease or condition is inflammatory bowel disease, rheumatoid arthritis, or systemic lupus erythematosus.
[0413] Further disclosed herein are methods for diagnosing and treating a disease or condition associated with xCT expression in a subject, including administering an effective amount of a compound of any one of Formula (I), Formula (la), Formula (lb), Formula (lb’), Formula (Ic), Formula (Id), Formula (le), Formula (If), or Formula (II), in accordance with the compounds of this disclosure. In certain examples, the disclosure relates to methods for diagnosing and treating a disease or condition associated with xCT expression in a subject, including administering an effective amount of a compound of Formula (I) in accordance with the compounds of this disclosure. In certain examples, the disclosure relates to methods for diagnosing and treating a disease or condition associated with xCT expression in a subject, including administering an effective amount of a compound of Formula (la) in accordance with the compounds of this disclosure. In certain examples, the disclosure relates to methods for diagnosing and treating a disease or condition associated with xCT expression in a subject, including administering an effective amount of a compound of Formula (lb) in accordance with the compounds of this disclosure. In certain examples, the disclosure relatesAtorney Docket No. 090723-1556314-25-044PCT
[0414] to methods for diagnosing and treating a disease or condition associated with xCT expression in a subject, including administering an effective amount of a compound of Formula (lb’) in accordance with the compounds of this disclosure. In certain examples, the disclosure relates to methods for diagnosing and treating a disease or condition associated with xCT expression in a subject, including administering an effective amount of a compound of Formula (Ic) in accordance with the compounds of this disclosure. In certain examples, the disclosure relates to methods for diagnosing and treating a disease or condition associated with xCT expression in a subject, including administering an effective amount of a compound of Formula (Id) in accordance with the compounds of this disclosure. In certain examples, the disclosure relates to methods for diagnosing and treating a disease or condition associated with xCT expression in a subject, including administering an effective amount of a compound of Formula (le) in accordance with the compounds of this disclosure. In certain examples, the disclosure relates to methods for diagnosing and treating a disease or condition associated with xCT expression in a subject, including administering an effective amount of a compound of Formula (If) in accordance with the compounds of this disclosure. In certain examples, the disclosure relates to methods for diagnosing and treating a disease or condition associated with xCT expression in a subject, including administering an effective amount of a compound of Formula (II) in accordance with the compounds of this disclosure.
[0415] In certain examples, the disclosure relates to methods for diagnosing and treating a disease or condition associated with xCT expression in a subject, including administering an effective amount of a composition including a compound of any one of Formula (I), Formula (la), Formula (lb), Formula (lb’ ), Formula (Ic), or Formula (Id), Formula (le), Formula (If), and a carrier. In certain examples, the disclosure relates to methods for inhibiting cystine / glutamate antiporter xCT, including administering an effective amount of a composition including a compound of Formula (I) and a carrier. In certain examples, the disclosure relates to methods for inhibiting cystine / glutamate antiporter xCT, including administering an effective amount of a composition including a compound of Formula (la) and a carrier. In certain examples, the disclosure relates to methods for inhibiting cystine / glutamate antiporter xCT, including administering an effective amount of a composition including a compound of Formula (lb) and a carrier. In certain examples, the disclosure relates to methods for inhibiting cystine / glutamate antiporter xCT, including administering an effective amount of a composition including a compound of Formula (lb’) and a carrier. In certain examples, the disclosure relates to methods for inhibiting cystine / glutamate antiporter xCT, including administering an effective amount of aAtorney Docket No. 090723-1556314-25-044PCT
[0416] composition including a compound of Formula (Ic) and a carrier. In certain examples, the disclosure relates to methods for inhibiting cystine / glutamate antiporter xCT, including administering an effective amount of a composition including a compound of Formula (Id) and a carrier. In certain examples, the disclosure relates to methods for inhibiting cystine / glutamate antiporter xCT, including administering an effective amount of a composition including a compound of Formula (le) and a carrier. In certain examples, the disclosure relates to methods for inhibiting cystine / glutamate antiporter xCT, including administering an effective amount of a composition including a compound of Formula (If) and a carrier.
[0417] In certain examples, the disclosure relates to methods for diagnosing and treating a disease or condition associated with xCT expression in a subject, including administering an effective amount of a pharmaceutical formulation including a compound of any one of Formula (I), Formula (la), Formula (lb), Formula (lb ’ ), Formula (Ic), or Formula (Id), or a pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable excipient or carrier. In certain examples, the disclosure relates to methods for diagnosing and treating a disease or condition associated with xCT expression in a subject, including administering an effective amount of a pharmaceutical formulation including a compound of Formula (I), or a pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable excipient or carrier. In certain examples, the disclosure relates to methods for diagnosing and treating a disease or condition associated with xCT expression in a subject, including administering an effective amount of a pharmaceutical formulation including a compound of Formula (la), or a pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable excipient or carrier. In certain examples, the disclosure relates to methods for diagnosing and treating a disease or condition associated with xCT expression in a subject, including administering an effective amount of a pharmaceutical formulation including a compound of Formula (lb), or a pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable excipient or carrier. In certain examples, the disclosure relates to methods for diagnosing and treating a disease or condition associated with xCT expression in a subject, including administering an effective amount of a pharmaceutical formulation including a compound of Formula (lb’), or a pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable excipient or carrier. In certain examples, the disclosure relates to methods for diagnosing and treating a disease or condition associated with xCT expression in a subject, including administering an effective amount of a pharmaceutical formulation including a compound of Formula (Ic), or aAtorney Docket No. 090723-1556314-25-044PCT
[0418] pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable excipient or carrier. In certain examples, the disclosure relates to methods for diagnosing and treating a disease or condition associated with xCT expression in a subject, including administering an effective amount of a pharmaceutical formulation including a compound of Formula (Id), or a pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable excipient or carrier.
[0419] In certain examples, the disease or condition associated with xCT-mediated cystineglutamate transport is cancer. In certain examples, the cancer is liver cancer, lung cancer, colorectal cancer, oral squamous cell carcinoma, bladder cancer, blood cancer, bone marrow cancer, brain cancer, breast cancer, bronchus cancer, cervical cancer, chondrosarcoma, endometrial cancer, gastrointestinal cancer, gastric cancer, esophageal cancer, genitourinary cancer, head and neck cancer, leukemia, lymphoma, ovarian cancer, pancreatic cancer, prostate cancer, renal cancer, skin cancer, testicular cancer, thyroid cancer, cholangiocarcinoma, or uterine cancer.
[0420] In certain examples, the disease or condition associated with xCT-mediated cystineglutamate transport is ferroptosis. In certain examples, the disease or condition is a neurodegenerative disorder. In some examples, the disease or condition is Alzheimer’s Disease (AD) or Parkinson’s Disease (PD), or schizophrenia. In certain examples, the disease or condition is amyotrophic lateral sclerosis. In certain examples, the disease or condition is oxidative stress. In certain examples, the disease or condition is a cardiovascular disease. In some examples, the disease or condition is ischemia-reperfusion injury or atherosclerosis, or heart failure. In certain examples, the disease or condition is an inflammatory disease. In some examples, the disease or condition is inflammatory bowel disease, rheumatoid arthritis, or systemic lupus erythematosus.
[0421] Also disclosed herein are methods for imaging cancerous cells in a subject, including administering an effective amount of a radiotracer selected from Formula (la) or Formula (lb):
[0422] O O 0 0
[0423]
[0424] Atorney Docket No. 090723-1556314-25-044PCT
[0425] or stereoisomers or salts thereof, wherein:
[0426] Y is a halogen or halogen isotope; and
[0427] m is 1, 2 or 3, wherein when m is 1, Y is halogen isotope, and when m is 2 or 3, at least one Y is halogen isotope; and
[0428] imaging the radiotracer using an imaging system.
[0429] In certain examples, the halogen isotope is [18F], [77Br], [76Br], [123I], [124I], [125I], [131I], or [211At]. In some examples, the halogen isotope is [18F] . In some examples, the halogen isotope is [77Br], In some examples, the halogen isotope is [76Br], In some examples, the halogen isotope is [123I], In some examples, the halogen isotope is [124I], In some examples, the halogen isotope is [125I], In some examples, the halogen isotope is [131I], In some examples, the halogen isotope is [211At] .
[0430] In certain examples, the halogen is F, Cl, Br, I, or At. In some examples, the halogen is F. In some examples, the halogen is Cl. In some examples, the halogen is Br. In some examples, the halogen is I. In some examples, the halogen is At.
[0431] In certain examples, the radiotracer is:
[0432] [18F]ZLF5 [123I]ZLF6 0 0 0 0
[0433]
[0434] [131I]ZLF7 [211At]ZLF8
[0435] or stereoisomers or salts thereof.
[0436] In certain examples, radiotracer imaging systems are systems that can capture the high-energy radiation of a radioactive atom to display in an image from a subject. As used herein, a “radiopharmaceutical,” “radiotracer,” “radioactive tracer,” or a “radioactive label” is a synthetic derivative of a natural compound in which one or more atoms have been replacedAtorney Docket No. 090723-1556314-25-044PCT
[0437] by a radionuclide that releases high-energy types of radiation. In certain examples, the imaging system used in the methods of the present disclosure is single photon emission computed tomography (SPECT) or positron emission tomography (PET), or positron emission mammography, or perturbed angle correlated spectroscopy, or scintigraphy. In certain examples, the imaging system used in the methods of the present disclosure is SPECT. In certain examples, the imaging system used in the methods of the present disclosure is PET.
[0438] Also disclosed herein are methods for imaging cancerous cells in a subject, including: administering an effective amount of a radiotracer of the following formula:
[0439] O O
[0440]
[0441] [18F]ZLF2
[0442] or stereoisomers or salts thereof; and
[0443] imaging the radiotracer using an imaging system.
[0444] In certain examples, the imaging system used in the methods of the present disclosure is single photon emission computed tomography (SPECT) or positron emission tomography (PET), or positron emission mammography, or perturbed angle correlated spectroscopy, or scintigraphy. In certain examples, the imaging system used in the methods of the present disclosure is SPECT. In certain examples, the imaging system used in the methods of the present disclosure is PET.
[0445] One or more aspects of the disclosure may be further understood by the following non-limiting examples.
[0446] EXAMPLES
[0447] Example 1. Synthesis of glutamate analogs developed as radiopharmaceuticals for imaging and therapy
[0448] A general schematic for the synthesis of glutamate analogs developed as radiopharmaceuticals for imaging and therapy can be found in Scheme 1.Attorney Docket No. 090723-1556314-25-044PCT
[0449] Scheme 1. Synthesis of glutamate analogs as radiopharmaceuticals for imaging and therapy.
[0450] L-Glutamic acid di-tert -butyl ester lnt-2, X = F lnt-3, X = Br lnt-4, X = I
[0451] lnt-3
[0452] ZLF6, X = Br ZLF7, X = I d
[0453] [18F]ZLF5, Y = [18F]
[0454] [123I]ZLF7, Y = [123l]
[0455] [131I]ZLF7, Y = [131l]
[0456]
[0457] [211At]ZLF8, Y = [211At] Reagents and conditions for each step of the reaction were set as follows: (a) (Boc)2O, triethylamine (EtsN), di chloromethane (DCM), at room temperature (r.t.) for 10 hours; (b) mixture with lithium bis(trimethylsilyl)amide (1.0 M in tetrahydrofuran (THF)), 3-Fluoropropyl trifluoromethanesulfonate added dropwise and stirred for 5 hours at -78 °C; (c) DCM, trifluoroacetic acid (TFA) at room temperature for 2 hours; (d) Bis(pinacolato)diboron (B2Pin2), potassium acetate (KO Ac), [l,r-Bis(diphenylphosphino)ferrocene]palladium(II) dichloride (Pd(dppf)C12), Dioxane at 90 °C for 4 hours; (e) Cu(pyridine)4(OTf) 23 °C, methanol (MeOH) / acetonitrile (CAN) for 10 minutes. [18F]KF / K222, or [123I]NaI, or [125I]NaI, or [124I]NaI, or [131I]NaI, or [211At]NaAt.Atorney Docket No. 090723-1556314-25-044PCT
[0458] Synthesis of (2S,4S)-2-amino-4-(4-jluorophenethyl)pentanedioic acid (ZLF5)
[0459]
[0460] ZLF5
[0461] A flame-dried flask with a magnetic stirrer bar was charged with dry dichloromethane (DCM) (100 mL) and L-glutamic acid di-tert-butyl ester (11.8 g, 40 mmol, 1 eq). Triethylamine (EtiN) (11 mL, 80 mmol, 2 equiv) and di -tert-butyl di carb onate (87.2 mg, 1 eq) were added to the mixture over 15 minutes. Each of the tri ethylamine and di -tert-butyl di carb onate was added with a syringe pump at 0 °C. The mixture was stirred at room temperature for 10 hours. The mixture was washed with sat. aq. Sodium carbonate (Na2COs) (100 mL). The aqueous layer was separated twice with DCM (2 x 60 mL). The organic phases were dried and filtered over magnesium sulfate (MgSCU). The organic phases were concentrated to obtain the product di-tert-butyl (tert-butoxycarbonyl)-L-glutamate (Scheme 1, Int-1). Int-1 (180 mg, 0.50 mmol) was dissolved in tetrahydrofuran (THF) (8 mL) and added to lithium bis(trimethylsilyl)amide in THF (1.0 M, 1.50 mmol) dropwise at -78 °C. The mixture was stirred for another 15 minutes. l-(2-bromoethyl)-4-fluorobenzene (254 mg, 1.25 mmol, 2.5 eq) was dissolved in THF (2 mL) and added dropwise to the mixture. The resulting mixture was stirred for 5 hours at -78 °C. Then, ammonium chloride (NH4CI) (sat, 12.5 mL) was added, and the resulting mixture was treated with DCM (25 mL) and H2O (12.5 mL). The organic extract was washed with brine, dried over MgSCU, filtered, and evaporated. The product Int-2 (Scheme 1) was chromatographed using high-performance liquid chromatography (HPLC) (ACN / H2O with 0.05% TFA). Trifluoro acetic acid (TFA, 1 mL) was added dropwise to a solution of Int-2 (40.3 mg) in DCM (2 mL). The mixture was stirred at room temperature for 1 hour and then evaporated. The residue was chromatographed on HPLC (ACN / H2O with 0.05% TFA) to afford ZLF5 (26.0 mg) as a white solid.
[0462] 'HNMR (500 MHz, DMSO-tL) 6 7.21 (m), 7.08 (m), 3.80 (dd, J = 8.3, 6.3 Hz), 2.59 (m), 2.54 (m), 2.03 (m), 1.90 (m), 1.78 (m), FIG. 1A.13CNMR(125 MHz, DMSO-tL) 6 175.6, 170.8, 161.6, 158.8, 137.5, 130.1, 130.0, 115.1, 115.0, 50.6, 40.4, 33.5, 32.1, 31.6, FIG. IB.
[0463] MS (ESI+): m / z = 270.1 [M + H]+.Atorney Docket No. 090723-1556314-25-044PCT
[0464] Synthesis of (2S,4S)-2-amino-4-(4-bromophenethyl)pentanedioic acid (ZLF6)
[0465]
[0466] ZLF6
[0467] A flame-dried flask with a magnetic stirrer bar was charged with dry dichloromethane (DCM) (100 mL) and L-glutamic acid di-tert-butyl ester (11.8 g, 40 mmol, 1 eq), Scheme 1.
[0468] Triethylamine (EtsN) (11 mL, 80 mmol, 2 equiv) and di -tert-butyl di carb onate (87.2 mg, 1 eq) were added to the mixture over 15 minutes. Each of the tri ethylamine and di -tert-butyl di carb onate was added with a syringe pump at 0 °C. The mixture was stirred at room temperature for 10 hours. The mixture was washed with sat. aq. Na2COs (100 mL). The aqueous layer was separated twice with DCM (2 x 60 mL). The mixture was washed with sat. aq. Sodium carbonate (Na2COs) (100 mL). The aqueous layer was separated twice with DCM (2 x 60 mL). The organic phases were dried and filtered over magnesium sulfate (MgSCU). The organic phases were concentrated to obtain the product di-tert-butyl (tert-butoxycarbonyl)-L-glutamate (Scheme 1, Int-1). Int-1 (195.0 mg, 0.54 mmol) was dissolved in tetrahydrofuran (THF) (10 mL) and added to lithium bis(trimethylsilyl)amide in THF (1.0 M, 1.60 mmol) dropwise at -78 °C. The mixture was stirred for another 15 minutes. l-(2-bromoethyl)-4-bromobenzene (246.9 mg, 1.36 mmol, 2.5 eq) was dissolved in THF (2 mL) and added dropwise to the mixture. The resulting mixture was stirred for 5 hours at -78 °C. Then, ammonium chloride (NH4CI) (sat, 12.5 mL) was added, and the resulting mixture was treated with DCM (25 mL) and H2O (12.5 mL). The organic extract was washed with brine, dried over MgSCU, filtered, and evaporated. The product Int-3 (Scheme 1) was chromatographed on HPLC (ACN / H2O with 0.05% TFA) to yield 55.0 mg. To a solution of Int-3 (15.1 mg) in DCM (2 mL) was added trifluoro acetic acid (TFA, 1 mL) dropwise. The mixture was stirred at room temperature for 1 hour and then evaporated. The residue was chromatographed using high-performance liquid chromatography (HPLC) (ACN / H2O with 0.05% TFA) to afford ZLF6 (4.0 mg) as a white solid.
[0469] ‘HNMR (500 MHz, DMSO-tfc) 67.46 (d, J= 8.2 Hz), 7.16 (d, J= 8.2 Hz), 3.75 (dd, J = 8.9, 6.2 Hz), 2.58 (m), 2.54 (m), 1.97 (m), 1.86 (m), 1.80 (m), 1.73 (m), FIG. 2A.13C NMR (125 MHz, DMSO-tfc) 6 175.4, 170.7, 140.8, 131.2, 130.6, 118.9, 115.0, 50.7, 40.4, 33.1, 32.2, 31.9, FIG. 2B. MS (ESI+): m / z = 330.0 [M + H]+.Atorney Docket No. 090723-1556314-25-044PCT
[0470] Synthesis of (2S,4S)-2-amino-4-(4-iodophenethyl)pentanedioic acid (ZLF7)
[0471]
[0472] ZLF7
[0473] A flame-dried flask with a magnetic stirrer bar was charged with dry dichloromethane (DCM) (100 mL) and L-glutamic acid di-tert-butyl ester (11.8 g, 40 mmol, 1 eq), Scheme 1.
[0474] Triethylamine (EtiN) (11 mL, 80 mmol, 2 equiv) and di -tert-butyl di carb onate (87.2 mg, 1 eq) were added to the mixture over 15 minutes. Each of the tri ethylamine and di -tert-butyl di carb onate was added with a syringe pump at 0 °C. The mixture was stirred at room temperature for 10 hours. The mixture was washed with sat. aq. Na2COs (100 mL). The aqueous layer was separated twice with DCM (2 x 60 mL). The mixture was washed with sat. aq. Sodium carbonate (Na2COs) (100 mL). The aqueous layer was separated twice with DCM (2 x 60 mL). The organic phases were dried and filtered over magnesium sulfate (MgSCU). The organic phases were concentrated to obtain the product di-tert-butyl (tertbutoxy carbonyl)-L-glutamate (Scheme 1, Int-1). Int-1 (180 mg, 0.50 mmol) was dissolved in tetrahydrofuran (THF) (8 mL) and added to lithium bis(trimethylsilyl)amide in THF (1.0 M, 1.50 mmol) dropwise at -78 °C. The mixture was stirred for another 15 minutes. l-(2-bromoethyl)-4-iodobenzene (254 mg, 1.25 mmol, 2.5 eq) in THF (2 mL) was then added dropwise to the mixture, and stirred for 5 hours at -78 °C. Then, ammonium chloride (NH4CI) (sat, 12.5 mL) was added, and the resulting mixture was treated with DCM (25 mL) and H2O (12.5 mL). The organic extract was washed with brine, dried over MgSCU, filtered, and evaporated. The product Int-3 was chromatographed on HPLC (ACN / H2O with 0.05% TFA). To a solution of Int-3 (11.0 mg) in DCM (2 mL) was added trifluoro acetic acid (TFA, 1 mL) dropwise. The mixture was stirred at room temperature for 1 hour and then evaporated. The residue was chromatographed on HPLC (ACN / H2O with 0.05% TFA) to afford ZLF7 (6.2 mg) as a white solid.
[0475] 'HNMR (500 MHz, DMSO-tL) 67.61 (d, J= 8.2 Hz), 6.69 (d, J= 8.2 Hz), 3.45 (m), 2.58 (m), 2.49 (m, overlapped), 1.85 (m), 1.73 (m), 1.49 (m), FIG. 3A.13C NMR (125 MHz, DMSO-tL) 6 175.1, 170.4, 141.6, 137.0, 130.8, 91.3, 51.7, 41.2, 33.7, 33.2, 32.5, FIG.3B. MS (ESI+): m / z = 378.0 [M + H]+.Atorney Docket No. 090723-1556314-25-044PCT
[0476] Synthesis of di-tert-butyl (2S,4S)-2-((tert-butoxycarbonyl)amino)-4-(4-(4,4,5,5-tetramethyl-1, 3, 2-dioxaborolan-2-yl)phene thyl)pentanedioate (ZLFB1 )
[0477]
[0478] A flame-dried flask with a magnetic stirrer bar was charged with dry dichloromethane (DCM) (100 mL) and L-glutamic acid di-tert-butyl ester (11.8 g, 40 mmol, 1 eq).
[0479] Triethylamine (EtsN) (11 mL, 80 mmol, 2 equiv) and di -tert-butyl di carb onate (87.2 mg, 1 eq) were added to the mixture over 15 minutes. Each of the triethylamine and di -tert-butyl di carb onate was added with a syringe pump at 0 °C. The mixture was stirred at room temperature for 10 hours. The mixture was washed with sat. aq. Sodium carbonate (Na2COs) (100 mL). The aqueous layer was separated twice with DCM (2 x 60 mL). The organic phases were dried and filtered over magnesium sulfate (MgSCU). The organic phases were concentrated to obtain the product di-tert-butyl (tert-butoxycarbonyl)-L-glutamate (Scheme 1, Int-1). Int-1 (195.0 mg, 0.54 mmol) was dissolved in tetrahydrofuran (THF) (10 mL) and added to lithium bis(trimethylsilyl)amide in THF (1.0 M, 1.60 mmol) dropwise at -78 °C. The mixture was stirred for another 15 minutes. l-(2-bromoethyl)-4-bromobenzene (246.9 mg, 1.36 mmol, 2.5 eq) was dissolved in THF (2 mL) and added dropwise to the mixture. The resulting mixture was stirred for 5 hours at -78 °C. Then ammonium chloride (NH4CI) (sat, 12.5 mL) was added, and the resulting mixture was treated with DCM (25 mL) and H2O (12.5 mL). The organic extract was washed with brine, dried over MgSCL, filtered, and evaporated. The product Int-3 (Scheme 1) was chromatographed using high performance liquid chromatography (HPLC) (ACN / H2O with 0.05% TFA). A mixture of compound Int-3 (55.0 mg, 10.4 pmol, 1 eq), Bis(pinacolato)diboron (JLPi ) (128.7 mg, 506.9 pmol, 5 eq), potassium acetate (AcOK) (39.8 mg, 405.5 pmol, 4 eq), 1,1'-Bis(diphenylphosphino)ferrocene]palladium(II) dichloride (Pd(dppf)C12) (7.4 mg, 10.1 pmol, 0.1 eq) in 5 mL dioxane. Following, the mixture was stirred at 90 °C for 1 hour under N2 gas atmosphere. The crude reaction mixture was extracted with 300 mL ethyl acetate (EtOAc).Atorney Docket No. 090723-1556314-25-044PCT
[0480] The. The residue was chromatographed on HPLC (ACN) to afford ZLFB1 (17.5 mg) as a gum solid.
[0481] 'HNMR (600 MHz, CDCh) 67.72 (d, J= 7.8), 7.19 (d, J= 7.8), 4.86 (d, J= 8.9 Hz, NH), 4.12 (m), 3.76 (m), 2.65 (m), 2.58 (m), 2.37 (m), 1.93 (m), 1.83 (m), 1.54 (m), 1.49 (s), 1.46 (m), 1.43 (s), 1.43 (s), 1.33 (s), FIG. 4A.13C NMR (150 MHz, CDCh) 6 175.0, 172.0, 155.6, 145.1, 135.1, 128.0, 83.8, 82.0, 81.0, 79.8, 54.5, 53.4, 43.4, 34.5, 34.5, 33.6, 28.4, 28.3, 28.1, 25.0, 25.0, 19.6, 18.4, FIG. 4B. MS (ESL): m / z = 590.6 [M + H]+.
[0482] Example 2. [18F] -Radiolabeling of the ZLFB1 Boronic Ester Precursor for the radiosynthesis of [18F]ZLF5
[0483] Scheme 2 shows a schematic for the radiosynthesis of [18F]ZLF5 with a radiochemical purity (RCP) = 100%.
[0484] Scheme 2. Radiosynthesis of [18F]ZLF5.
[0485] K[18F]F-K222 I DMF, 110 °C, 20 min* 1. Cu OTf)2Pydeprotectjon110 °C, 5 min 2. 8 N H2SO4h3. Purification via HPLC, gentisic acid 4. tC18 plus long cartridge
[0486]
[0487] 5. Elute with ethanol18
[0488]
[0489] 6. Reformulate with PBS (0.6% sodium ascorbate) F]ZLF5
[0490] Radioactive fluoride-18 ([ F]fluoride) dissolved in 1.0-1.5 mL of enriched oxygen-18 18
[0491] ( O) water produced by cyclotron was purified and concentrated using a pre-conditioned 18
[0492] quaternary methyl ammonium (QMA) anion exchange cartridge. The trapped [ F]fluoride was eluted from the cartridge into the quartz glass reactor used for chemical reaction and radiolabeling with 0.9 mL of the potassium carbonate / Kryptofix (K222) solution. The 18
[0493] K222 / [ F]KF complex was heated to 100 °C and dried under vacuum and nitrogen gas flow for 4 minutes. Acetonitrile (0.7 mL) was added to azeotropically dry the complexed activity at 120 °C under vacuum and nitrogen gas flow for 2 minutes, followed by vacuum for 1 minute. Boronic ester precursor (5-12 mg) was dissolved in 1.0 mL DMF containing Cu(pyridine)4(OTf)2catalyst in approximately twice the mass amount of the precursor. The 18
[0494] homogeneous mixture was added to the dried K222 / [ F]KF complex activity and stirred at 110 °C for 20 minutes, then cooled to 45 °C. A 1 mL of 8 N sulfuric acid (H2SO4) was transferredAtorney Docket No. 090723-1556314-25-044PCT
[0495] to the reaction mixture and heated at 110 °C for 5 minutes to promote full deprotection. Upon cooling to 45 °C, the reaction mixture is passed through the glass filter / Alumina N light cartridge (to remove unreacted fluoride and copper-derived solid residues) to the intermediate vial containing 500 pL of gentisic acid (10 mg / 1 mL water). The reactor is rinsed with 2.0 mL HPLC mobile phase solution and, again, transferred through the filter / Alumina cartridge to the intermediate vial. The solution is thoroughly mixed by bubbling nitrogen gas and injected into the HPLC for purification. Purification was performed using 0.1% TFA in water / Acetonitrile 18
[0496] (4:1, v / v) at 4 mL / min flow rate and C18 semiprep column. The [ F]ZLF5 product is eluted at about 14-15 minutes. The purified fraction is collected in the dilution flask containing 50 mL water (plus 500 pL of gentisic acid) and passed through a tC18 plus long cartridge (preconditioned with 5 mL of ethanol and 10 mL of water). The trapped product is rinsed with 6 mL water and eluted with 1 mL of absolute ethanol and reformulated with 0.6% sodium ascorbate (w / v) in PBS (pH 8.0).
[0497] Alternatively, the ethanol fraction collected from the cartridge was evaporated to dryness and redissolved in 1 mL of 0.6% sodium ascorbate (w / v) in PBS. Analytical HPLC 18
[0498] showed that the [ F]ZLF5 final product had a radiochemical purity (RCP) of 100% (FIG.5A)
[0499] 18
[0500] and pH at 7. The [ F]ZLF5 final product and ZLF5 reference standard elute at 11.1-11.2 minutes.
[0501] Example 3. [131I]-Radiolabeling of the ZLFB1 Boronic Ester Precursor for the radiosynthesis of [131I]ZLF7
[0502] Scheme 3 shows a schematic for the radiosynthesis of [131I]ZLF7 with a radiochemical purity (RCP) = 100%.
[0503] Scheme 3. Radiosynthesis of [131I]ZLF7.
[0504] [131l]l in NaCI 1. 0.1 M NaOH in MeOH 2. Precursor in MeCN 3. Cu(OTf)2Py4in MeOH, RT, varies 4. Quench with, H,O deprotection, 95 „ 5. 8 N H2SO4hC, 5
[0505]
[0506] ZLFB1 6. Purification via HPLC [131I]ZLF7
[0507] 7. tC18 SPE, PBS (0.6% sodium ascorbate)
[0508] reformulationAtorney Docket No. 090723-1556314-25-044PCT
[0509] ZLFB1 precursor (3-6 mg) was dissolved in 100 pL of acetonitrile (MeCN). Cu(pyridine)4(OTf)2, 2-3 times the mass ratio of the precursor, was dissolved in 200 pL of methanol and added to the precursor solution. The solution mixture was added to a 4 mL glass tube containing a 100 pL 0.1 M sodium hydroxide (NaOH) methanolic solution of [131I] (0.04 - 1 GBq). The tube was then vortexed and allowed to react at room temperature for 10 minutes, followed by the addition of 100 pL of water to quench the reaction. A 400 pL solution of 8 N sulfuric acid (H2SO4) was transferred to the tube and heated at 95 °C for 5 minutes to promote full deprotection. Afterward, the solution was allowed to cool down to room temperature. Note: the solution can undergo purification as is or be diluted in PBS to enhance stability. The solution was purified using the Agilent® HPLC 1290 system (Agilent Technologies, Inc., Santa Clara, CA) equipped with a radio detector. The fractionated collection from the HPLC was diluted in 15-20 mL of water and passed through a tC18 Plus short cartridge (preconditioned with 5 mL of ethanol and 10 mL of water). The trapped [131I]ZLF7 product was rinsed with 6 mL water and eluted with 0.5-1.0 mL of absolute ethanol, Scheme 3. The content was then reformulated with 0.6% sodium ascorbate (w / v) in PBS (pH 8.0).
[0510] Alternatively, the ethanol fraction collected from the cartridge was evaporated to dryness at 60 °C under vacuum and nitrogen flow, and redissolved in 1 mL of 0.6% sodium ascorbate (w / v) in PBS. Analytical HPLC showed that the [131I]ZLF7 final product had a radiochemical purity (RCP) of 100% (FIG. 5B) and pH at 7. The [131I]ZLF7 final product and ZLF7 reference standard elute around 12.0 minutes.
[0511] The purification and analysis of the product were performed using the following same system and settings: Mobile Phase: 0.1% TFA in water (A), 0.1%TFA in acetonitrile (B); Flow = 1 mL / min; Phenomenex Gemini C-18 column (150 x 4.60 mm, 5 pm), VWD = 254 nm; Gradient: 0-2 minutes (95% A, 5% B), 2-15 minutes (5% A, 95% B) isocratic hold to 21 minutes.
[0512] Example 4. [18F] -Radiolabeling of the ZLFB2 Boronic Ester Precursor for the radiosynthesis of [18F]ZLF16
[0513] Scheme 4 shows a schematic for the radiosynthesis of [18F]ZLF16 with a radiochemical purity (RCP) = 100%.Atorney Docket No. 090723-1556314-25-044PCT
[0514] Scheme 4. Radiosynthesis of [ ’F]ZLF16.
[0515] K[18F]F-K222 „ ~ „ / DMF, 110 °C, 20 min* 1. Ou OTf)2Pydeprotectioni110°C, 5 min 2. 8 N H2SO4h3. Purification via HPLC, gentisic acid 4. tC18 plus long cartridge 5. Elute with ethanol
[0516]
[0517] 6. Reformulate with PBS (0.6% sodium ascorbate) Radioactive fluoride-18 ([ F]fluoride) dissolved in 1.0-1.5 mL of enriched oxygen-18 18
[0518] ( O) water produced by cyclotron was purified and concentrated using a pre-conditioned 18
[0519] quaternary methyl ammonium (QMA) anion exchange cartridge. The trapped [ F]fluoride was eluted from the cartridge into the quartz glass reactor used for chemical reaction and radiolabeling with 0.9 mL of the potassium carbonate / Kryptofix (K222) solution. The 18
[0520] K222 / [ F]KF complex was heated to 100 °C and dried under vacuum and nitrogen gas flow for 4 minutes. Acetonitrile (0.7 mL) was added to azeotropically dry the complexed activity at 120 °C under vacuum and nitrogen gas flow for 2 minutes, followed by vacuum for 1 minute. Boronic ester precursor (5-12 mg) was dissolved in 1.0 mL DMF containing Cu(pyridine)4(OTf)2catalyst in approximately 1-2 times the mass amount of the precursor. The 18
[0521] homogeneous mixture was added to the dried K222 / [ F]KF complex activity and stirred at 110 °C for 20 minutes, then cooled to 45 °C. A 1 mL of 8 N sulfuric acid (H2SO4) was transferred to the reaction mixture and heated at 110 °C for 5 minutes to promote full deprotection. Upon cooling to 45 °C, the reaction mixture is passed through the glass filter / Alumina N light cartridge (to remove unreacted fluoride and copper-derived solid residues) to the intermediate vial containing 500 pL of gentisic acid (10 mg / 1 mL water). The reactor is rinsed with 2.0 mL HPLC mobile phase solution and, again, transferred through the filter / Alumina cartridge to the intermediate vial. The solution is thoroughly mixed by bubbling nitrogen gas and injected into the HPLC for purification. Purification was performed using 0.1% TFA in water / Acetonitrile (4:1, v / v) at 4 mL / min flow rate and C18 semiprep column. After 20 minutes runtime, switch mobile phase to 0.1% TFA in water / Acetonitrile (3 :2, v / v) at 4 mL / min flow rate and continue 18
[0522] purifying. The [ F]ZLF16 product is eluted at about 27 minutes. The purified fraction is collected in the dilution flask containing 50 mL water (plus 500 pL of gentisic acid) and passed through an tC 18 plus long cartridge (pre-conditioned with 5 mL of ethanol and 10 mL of water).Atorney Docket No. 090723-1556314-25-044PCT
[0523] The trapped product is rinsed with 6 mL water and eluted with 1.0 mL of absolute ethanol and reformulated with 0.6% sodium ascorbate (w / v) in PBS (pH 8.0).
[0524] Alternatively, the ethanol fraction collected from the cartridge was evaporated to dryness and redissolved in 1 mL of 0.6% sodium ascorbate (w / v) in PBS. Analytical HPLC 18
[0525] showed that the [ F]ZLF16 final product had a radiochemical purity (RCP) of 100% (FIG.
[0526] 18
[0527] 6A) and pH at 7. The [ F]ZLF16 final product and ZLF16 reference standard elute around 11.6-11.7 minutes.
[0528] Example 5. [131I]-Radiolabeling of the ZLFB2 Boronic Ester Precursor for the radiosynthesis of [131I]ZLF18
[0529] Scheme 5 shows a schematic for the radiosynthesis of [131I]ZLF18 with a radiochemical purity (RCP) = 100%.
[0530] Scheme 5. Radiosynthesis of [131I]ZLF18.
[0531] [131l]l in NaCI 1. 0.1 M NaOH in MeOH 2. Precursor in MeCN 3. Cu(OTf)2Py4in MeOH, RT, varies 4. Quench with, H2O,x.
[0532] deprotection, 95n
[0533]
[0534] 5. 8 N H2SO40, 5 min 6. Purification via HPLC
[0535] 7. tC18 SPE, PBS (0.6% sodium ascorbate)
[0536] reformulation
[0537] ZLFB2 boronic ester precursor (3-6 mg) was dissolved in 100 pL of acetonitrile (MeCN). Cu(pyridine)4(OTf)2, 2-3 times the mass ratio of the precursor, was dissolved in 200 pL of methanol and added to the precursor solution. The solution mixture was added to a 4 mL 131 glass tube containing a 100 pL 0.1 M sodium hydroxide (NaOH) methanolic solution of [ I] (0.04- 1 GBq). The tube was then vortexed and allowed to react at room temperature for 10 minutes, followed by the addition of 100 pL of water to quench the reaction. A 400 pL solution of 8 N sulfuric acid (H2SO4) was transferred to the tube and heated at 95 °C for 5 minutes to promote full deprotection. Afterward, the solution was allowed to cool down to room temperature. Note: the solution can undergo purification as is or be diluted in PBS to enhance stability. The solution was purified using the Agilent® HPLC 1290 system (Agilent Technologies, Inc., Santa Clara, CA) equipped with radio-detector. The fractionated collection from the HPLC was diluted in 15-20 mL of water and passed through a tC18 Plus shortAtorney Docket No. 090723-1556314-25-044PCT
[0538] cartridge (pre-conditioned with 5 mL of ethanol and 10 mL of water). The trapped [ I]ZLF18 product was rinsed with 6 mL water and eluted with 0.5-1.0 mL of absolute ethanol, Scheme 5. The content was then reformulated with 0.6% sodium ascorbate (w / v) in PBS (pH 8.0).
[0539] Alternatively, the ethanol fraction collected from the cartridge was evaporated to dryness at 60 °C under vacuum and nitrogen flow, and redissolved in 1 mL of 0.6 % sodium 131
[0540] ascorbate (w / v) in PBS. Analytical HPLC showed that the [ I]ZLF18 final product had a 131
[0541] radiochemical purity (RCP) of 100% (FIG.6B) and pH at 7. The [ I]ZLF 18 final product and ZLF18 reference standard elute around 12.3-12.4 minutes.
[0542] The purification and analysis of the product were performed using the following same system and settings: Mobile Phase: 0.1% TFA in water (A), 0.1% TFA in acetonitrile (B); Flow = 1 mL / min; Phenomenex Gemini C-18 column (150 x 4.60 mm, 5pm), VWD = 254 nm; Gradient: 0-2 minutes (95% A, 5% B), 2-15 minutes (5% A, 95% B) isocratic hold to 21 minutes.
[0543] Example 6. [131I]ZLF7 cell uptakes in different cancer cell lines
[0544] Cells with different levels of xCT expression were chosen for cell uptake assay.
[0545] H460, A549, H520 and HT29 cells were seeded in 24-well plates. The cell number used for seeding was adjusted for each cell line to yield approximately 100,000 cells per well on the day of the uptake study. Cells were allowed to grow for 2 days under standard conditions (37 °C, 5% CO2). The cell number at the time of uptake assay was determined by detaching cells in three (3) representative wells and counting the cells using a Bio-Rad® TC20™ automated cell counter (Bio-Rad Laboratories, Hercules, CA). All uptake data was normalized to total added radioactivity and 100,000 cell number. The cells were washed twice with phosphate-buffered saline (PBS), [131I]ZLF7 (18.5 kBq / well) in 0.5 mL of PBS containing 0.1% bovine serum albumin (BSA) was added to each well. For blocking experiment, FIG. 7A and FIG.
[0546] 7B, cold ZLF7 (0.5 mM) was mixed with [131I]ZLF7 and added to each well. The cells were incubated at 37 °C. Tracer uptake was stopped by removal of the assay buffer at the indicated time points. Cells were quickly washed three times with ice-cold PBS. To measure membrane-bound radioactivity, FIG. 8A and Fig. 8B, the cells were incubated with strip buffer (0.1 M sodium acetate in 154 mM sodium chloride (NaCl), pH 2-3) at 0 °C for 15 minutes. The strip solution was collected for gamma counting. The cells were lysed with addition of 0.1 M NaOH, the cell lysate was collected. Radioactivity of the strip solution and the cell lysate were determined by a LabLogic gamma counter (LabLogic, Sheffield, UnitedAtorney Docket No. 090723-1556314-25-044PCT
[0547] Kingdom). Total cell uptake is the addition of membrane-bound and internalized (cell lysate) radioactivity.
[0548] Example 7. [18F]FSPG uptake assay on A549 cells
[0549] ZLF5, ZLF6, and ZLF7 as competitors
[0550] The A549 cell seeding on a 24-well plate yielded approximately 105cells / well (500 pL) at the day of the uptake study. Cells were grown for 1.5 days under standard conditions (37 °C, 5% CO2). Cell culture medium was removed, and the cells were washed twice with phosphate-buffered saline (PBS). Radiotracers were added to the assay buffer (PBS / 0.1% w / v bovine serum albumin (BSA)) by using 5 pCi / well for [18F]-labeled FSPG. Cells were co-incubated with competitors in excess at 100 pmol / L, for 60 minutes. Tracer uptake was stopped by the removal of the assay buffer. Cells were quickly washed three times with PBS and lysed by adding 1 N NaOH (0.5 mL). The cell lysate was removed from the plates and transferred to the tubes. The radioactivity of [18F]-samples was determined in a gamma counter. Data of [18F]FSPG uptake is summarized in Table 1, below. Compounds ZLF5-ZLF7 are shown as competitive inhibitors of [18F]FSPG accumulation in cancer cells, showing the cellular uptake percentage compared to the vehicle control (i.e., DMSO) (FIG. 9).
[0551] Table 1. [18F]FSPG uptake assay on A549 lung cancer cells Compound [18F]FSPG uptake (%
[0552] compared with control)
[0553] Vehicle Control 100 %
[0554] FSPG (positive control) 17.3 %
[0555] ZLF5 26.7 %
[0556] ZLF6 14.4 %
[0557]
[0558] ZLF7 12.4 %
[0559] Example 8. [18F]FSPG uptake assay and [14C]Cystine uptake assay on H460 cells [18F]FSPG uptake assay: ZLF1, ZLF2, ZLF3, ZLF4, ZLF5, ZLF6, and ZLF7
[0560] The H460 cell seeding on a 24-well plate yielded approximately 105cells / well (500 pL) at the day of the uptake study. Cells were grown for 1.5 days under standard conditions (37 °C, 5% CO2). Cell culture medium was removed, and the cells were washed twice with phosphate-buffered saline (PBS). Radiotracers were added to the assay buffer (PBS / 0.1% w / v bovine serum albumin (BSA)) by using 5 pCi / well for [18F]-labeled IKE. Cells were coincubated with competitors in excess at 100 pmol / L, for 60 minutes. Tracer uptake was stopped by the removal of the assay buffer. Cells were quickly washed three times with PBS and lysed by adding 1 N NaOH (0.5 mL). The cell lysate was removed from the plates andAtorney Docket No. 090723-1556314-25-044PCT
[0561] transferred to the tubes. The radioactivity of [18F]-samples was determined in a gamma counter. Data of [18F]FSPG uptake is summarized in Table 2, below. Compounds
[0562] ZLF1-ZLF7 are shown as competitive inhibitors of [18F]FSPG accumulation in cancer cells, showing the cellular uptake percentage compared to the vehicle control (i.e., DMSO), FIG.
[0563] 10A
[0564] Table 2. [18F]FSPG uptake assay on H460 lung cancer cells Compound [18F]FSPG uptake (%
[0565] compared with control)
[0566] Vehicle Control 100 %
[0567] FSPG (positive control) 18.4 %
[0568] ZLF1 26.3 %
[0569] ZLF2 29.5 %
[0570] ZLF3 35.1 %
[0571] ZLF4 32.7 %
[0572] ZLF5 17.9 %
[0573] ZLF6 13.4 %
[0574]
[0575] ZLF7 11.6 %
[0576] [I4C]Cystine uptake assay: ZLF5, ZLF6, and ZLF7 as competitors
[0577] H460 cell were seeded on a 96-well plate to yield approximately 2 *105cells / well (100 pL) at the day of the uptake study. Cells were grown for 1.5 days under standard conditions (37 °C, 5% CO2). Cell culture medium was removed, and the cells were washed twice with phosphate-buffered saline (PBS). Radiotracers were added to the Na+free assay buffer (137 mM Choline Chloride, 3 mM potassium chloride (KC1), 1 mM calcium chloride (CaCh), 1 mM magnesium chloride (MgCh), 5 mM D-Glucose, 0.7 mM dipotassium phosphate (K2HPO4), 10 mM HEPES (4-(2-hydroxyethyl)piperazine-l -ethane-sulfonic acid)) by using 0.012 pCi / well for [14C]cystine. Cells were co-incubated with competitors at different concentrations, for 60 minutes. Tracer uptake was stopped by the removal of the assay buffer. Cells were quickly washed three times with PBS and lysed by adding 0.1 N NaOH (50 pL). The cell lysate was removed from the plates and transferred to the tubes. Following, scintillation liquid 150 pL / well was added and the plate was sealed and incubated at room temperature for 2 hours to overnight before reading. The radioactivity of [14C]cystine was determined on a Hidex Sense Beta Plate Reader (Hindex, Turku, Finland). Compounds ZLF5-ZLF7 are shown as competitive inhibitors of [14C]cystine accumulation in cancer cells, showing the cellular uptake percentage compared to the vehicle control (i.e., DMSO), FIG.
[0578] 10BAttorney Docket No. 090723-1556314-25-044PCT
[0579] Table 3. [14C]Cys uptake assay on H460 lung cancer cells Compound [14C]Cys uptake (% compared
[0580] with control)
[0581] FSPG (positive control) 20.8 %
[0582] ZLF5 34.5 %
[0583] ZLF6 20.6 %
[0584] ZLF7 18.3 %
[0585] ZLF16 14.8 %
[0586] ZLF18 7.7 %
[0587]
[0588] ZLF21 16.9 %
[0589] Example 9. Synthesis of small molecule inhibitors of cystine / glutamate antiporter xCT A general schematic for the synthesis small molecule inhibitors of cystine / glutamate antiporter xCT can be found in Scheme 6.
[0590] Scheme 6. Synthesis small molecule inhibitors of cystine / glutamate antiporter xCT.
[0591]
[0592] Reagents and conditions for each step of the reactions are as follows: (a) phosphorus trichloride (PCh), N,N-Diisopropylethylamine (DIPEA), 1.5 M dioxane at 70 °C for 8 hours;Atorney Docket No. 090723-1556314-25-044PCT
[0593] (b) 0.2 M tetrahydrofuran (THF) at room temperature for 12 hours; (c) dichloromethane (DCM) add diisopropylethylamine (EDIP A) at 70 °C, warm to room temperature, and add 4-Dimethylaminopyridine (4-DMAP), stir for 2 hours; (d) sodium triacetoxyborohyride (NaBH(AcO)s), DCM, at room temperature for 2 hours.
[0594] Synthesis of 2-( 4-(2-( 4-chlorophenoxy)acetyl)piperazin-l-yl)methyl)-3-isobutylqumazolin- 4(3H)-one (ZLB1)
[0595]
[0596] ZLB1
[0597] N,N-Diisopropylethylamine (DIPEA) (728.7 mg, 5.64 mmol) was added to a solution of 2-(2-chloroethanamido)benzoic acid (1 g, 4.7 mmol) at room temperature (r.t.) in dioxane (0.2 M, 23.5 ml) and stirred for 2 minutes before the dropwise addition of phosphorous trichloride (772.7 mg, 5.64 mmol). After 10 minutes of stirring at r.t., 2-isobutykamine (308.8 mg, 4.23 mmol) was added dropwise as a 1.5 M solution (2.8 ml) in dioxane and the resulting mixture was heated to 70 °C and stirred for an additional 8 hours. The quinazolinone intermediate of 2-(chloromethyl)-3-isobutylquinazolin-4(3H)-one (Scheme 6, int-8) was generated and then purified by silica gel column chromatography and immediately used for the next step. Piperazine (516.8 mg, 6.00 mmol) was added to a solution of the quinazolinone intermediate int-8 (501.5 mg, 2.00 mmol) in tetrahydrofuran (THF) (0.2 M) and the resulting mixture was stirred at r.t. for 12 hours. The reaction mixture was then concentrated under reduced pressure. High performance liquid chromatography (HPLC) afforded the corresponding 3-isobutyl-2-(piperazin-l-ylmethyl)quinazolin-4(3H)-one (Scheme 6, int-9).
[0598] Then the piperazine quinazolinone int-9 was dissolved in dichloromethane (DCM) and ethyldiisopropylamine (EDIP A) (1.2 eq) was added at r.t.. The mixture was then cooled at 0 °C, followed by additional 4-chlorophenoxyacetyl chloride (1.2 eq) and 4-dimethylaminopyridine (4-DMAP) (0.5 eq). The reaction was slowly warmed to r.t. and stirredAtorney Docket No. 090723-1556314-25-044PCT
[0599] for 2 hours. The product was purified by HPLC (ACN / H2O with 0.1% TFA) to afford ZLB1 as a yellow gum (30.5 mg).
[0600] 'HNMR (600 MHz, CDCh) 68.12 (d, J= 8.0 Hz), 7.65 (dd, J= 2.2, 2.2 Hz), 7.47 (d, J= 8.1 Hz), 7.41 (dd, J= 7.8, 7.8 Hz), 7.11 (d, J= 7.8 Hz), 6.71 (d, J= 8.0 Hz), 4.59 (s), 4.32 (s), 3.72 (d, J= 6.2 Hz), 3.43 (br s), 3.35 (m), 1.96 (m), 0.81 (d, J= 8.3 Hz).13C NMR (150 MHz, CDCh) 6 167.1, 161.2, 156.0, 147.7, 144.1, 135.4, 129.9, 129.9, 128.7, 127.5, 127.4, 126.2, 120.4, 118.29, 115.9, 115.9, 67.7, 56.9, 53.4, 53.3, 50.2, 42.8, 39.6, 28.4, 20.0, 20.0. MS (ESI+): m / z = 469.4 [M + H]+.
[0601] Synthesis of 2-( 4-(5-chloro-lH-indole-2-carbonyl)piperazin-l-yl)methyl)-3-isobutylquinazolin-4( 3H)-one (ZLB2)
[0602]
[0603] N,N-Diisopropylethylamine (DIPEA) (728.7 mg, 5.64 mmol) was added to a solution of 2-(2-chloroethanamido)benzoic acid (1 g, 4.7 mmol) at room temperature (r.t.) in dioxane (0.2 M, 23.5 ml) and stirred for 2 minutes before the dropwise addition of phosphorous trichloride (222.2 mg, 5.64 mmol). After 10 minutes of stirring at r.t., 2-isobutykamine (308.8 mg, 4.23 mmol) was added dropwise as a 1.5 M solution (2.8 ml) in dioxane and the resulting mixture was heated to 70 °C and stirred for an additional 8 hours. The quinazolinone intermediate of 2-(chloromethyl)-3-isobutylquinazolin-4(3H)-one (Scheme 6, int-8) was generated and then purified by silica gel column chromatography and immediately used for the next step. Piperazine (516.8 mg, 6.00 mmol) was added to a solution of the quinazolinone intermediate int-8 (501.5 mg, 2.00 mmol) in tetrahydrofuran (THF) (0.2 M) and the resulting mixture was stirred at r.t. for 12 hours. The reaction mixture was then concentrated under reduced pressure. High performance liquid chromatography (HPLC) afforded the corresponding piperazine quinazolinone (Scheme 6, int-9). Then the piperazine quinazolinone int-9 was dissolved in dichloromethane (DCM) and ethyldiisopropylamine (EDIP A) (1.2 eq)Atorney Docket No. 090723-1556314-25-044PCT
[0604] was added at r.t.. The mixture was then cooled at 0 °C, followed by additional 5-chloro-UT-indole-2-carbonyl chloride (1.2 eq) and 4-dimethylaminopyridine (4-DMAP) (0.5 eq). The reaction was slowly warmed to r.t. and stirred for 2 hours. The product was purified by HPLC (ACN / H2O with 0.1% TFA) to afford ZLB2 as a yellow gum (30.5 mg).
[0605] 'HNMR (600 MHz, CDCI3) 68.28 (d, J= 8.0 Hz), 7.83 (dd, J= 7.7, 7.7 Hz), 7.70 (d, J= 8.1 Hz), 7.60 (overlapped), 7.59 (overlapped), 7.36 (d, J = 8.8 Hz), 7.26 (overlapped), 6.78 (s), 4.49 (s), 4.39 (s), 3.88 (d, J= 7.1 Hz), 3.59 (br s), 2.12 (m), 0.98 (d, J= 6.7 Hz).13C NMR (150 MHz, CDCI3) 6 168.7, 161.2, 161.2, 147.9, 143.8, 135.7, 134.7, 128.9, 128.1, 127.5, 127.0, 126.2, 126.0, 121.4, 120.4, 113.3, 106.4, 77.4, 77.2, 76.9, 57.1, 53.7, 53.7, 53.7, 53.7, 50.3, 28.4, 20.1, 20.1. MS (ESI+): m / z = 478.4 [M + H]+.
[0606] Synthesis of 2-( 4-( 4-hydroxypyridin-2-yl)methyl)piperazin-l-yl)methyl)-3-isobutylquinazolin-4( 3H)-one (ZLB7)
[0607]
[0608] ZLB7
[0609] N,N-Diisopropylethylamine (DIPEA) (728.7 mg, 5.64 mmol) was added to a solution of 2-(2-chloroethanamido)benzoic acid (1 g, 4.7 mmol) at room temperature (r.t.) in dioxane (0.2 M, 23.5 ml) and stirred for 2 minutes before the dropwise addition of phosphorous trichloride (J'll.'l mg, 5.64 mmol). After 10 minutes of stirring at r.t., 2-isobutykamine (308.8 mg, 4.23 mmol) was added dropwise as a 1.5 M solution (2.8 ml) in dioxane and the resulting mixture was heated to 70 °C and stirred for an additional 8 hours. The quinazolinone intermediate of 2-(chloromethyl)-3-isobutylquinazolin-4(3H)-one (Scheme 6, int-8) was generated and then purified by silica gel column chromatography and immediately used for the next step. Piperazine (516.8 mg, 6.00 mmol) was added to a solution of the quinazolinone intermediate int-8 (501.5 mg, 2.00 mmol) in tetrahydrofuran (THF) (0.2 M) and the resulting mixture was stirred at r.t. for 12 hours. The reaction mixture was then concentrated under reduced pressure. High performance liquid chromatography (HPLC) afforded the corresponding piperazine quinazolinone (Scheme 6, int-9). 4-Hydroxy-picolinaldehyde (31.4Atorney Docket No. 090723-1556314-25-044PCT
[0610] mg, 0.20 mmol), was added to piperazine quinazolinone int-9 (38.0 mg, 0.13 mmol) followed by sodium triacetoxyborohydride (40.2 mg, 0.19 mmol). The reaction was stirred at r.t. for 2 hours. The product was purified by HPLC chromatography (ACN / H2O with 0.1% TFA) to afford ZLB7 as a yellow gum (40.3 mg).
[0611] ‘HNMR (600 MHz, CD3OD) 88.29 (d, J= 2.7 Hz), 8.23 (d, J= 8.1 Hz), 7.86 (dd, J = 8.5, 7.1 Hz), 7.78 (d, J= 8.2 Hz), 7.76 (overlapped), 7.75 (overlapped), 7.59 (dd, J= 7.5, 7.5 Hz), 4.13 (s), 4.00 (d, J= 7.6 Hz), 3.57 (br s), 3.17 (t, J= 4.5 Hz), 2.20 (m), 0.99 (d, J= 6.7 Hz).13C NMR (150 MHz, CD3OD) 6 163.3, 157.4, 150.6, 146.7, 143.2, 136.1, 133.2, 131.4, 129.0, 128.5, 127.8, 127.7, 121.8, 58.7, 53.4, 51.1, 50.9, 29.3, 20.2, 20.2. MS (ESI+): m / z = 408.3 [M + H]+.
[0612] Synthesis of 3-isobutyl-2-((4-(quinolm-2-ylmethyl)piperazm-l-yl)methyl)qumazolm-4(3H)-one (ZLB8)
[0613] N'
[0614]
[0615] ZLB8
[0616] N,N-Diisopropylethylamine (DIPEA) (728.7 mg, 5.64 mmol) was added to a solution of 2-(2-chloroethanamido)benzoic acid (1 g, 4.7 mmol) at room temperature (r.t.) in dioxane (0.2 M, 23.5 ml) and stirred for 2 minutes before the dropwise addition of phosphorous trichloride (772.7 mg, 5.64 mmol). After 10 minutes of stirring at r.t., 2-isobutykamine (308.8 mg, 4.23 mmol) was added dropwise as a 1.5 M solution (2.8 ml) in dioxane and the resulting mixture was heated to 70 °C and stirred for an additional 8 hours. The quinazolinone intermediate of 2-(chloromethyl)-3-isobutylquinazolin-4(3H)-one (Scheme 6, int-8) was generated and then purified by silica gel column chromatography and immediately used for the next step. Piperazine (516.8 mg, 6.00 mmol) was added to a solution of the quinazolinone intermediate int-8 (501.5 mg, 2.00 mmol) in tetrahydrofuran (THF) (0.2 M) and the resulting mixture was stirred at r.t. for 12 hours. The reaction mixture was then concentrated under reduced pressure. High performance liquid chromatography (HPLC) afforded theAtorney Docket No. 090723-1556314-25-044PCT
[0617] corresponding 3-isobutyl-2-(piperazin-l-ylmethyl)quinazolin-4(3H)-one (Scheme 6, int-9). 2-quinolinecarboxaldehyde (31.4 mg, 0.20 mmol), was added to piperazine quinazolinone int-9 (40.0 mg, 0.13 mmol) followed by sodium triacetoxyborohydride (42.3 mg, 0.20 mmol). The reaction was stirred at r.t. for 2 hours. The product was purified by HPLC chromatography (ACN / H2O with 0.1% TFA) to afford ZLB8 as a yellow gum (40.3 mg).
[0618] ‘H NMR (500 MHz, CDCI3) 6 8.89 (d, J= 8.2 Hz), 8.41 (d, J= 8.7 Hz), 8.27 (d, J = 7.9 Hz), 8.16 (d, J= 8.2 Hz), 8.11 (dd, J= 7.8, 7.8 Hz), 8.01 (d, J= 8.2 Hz), 7.92 (dd, J= 7.6, 7.6 Hz), 7.84 (dd, J= 7.6, 7.6 Hz), 7.76 (d, J= 8.2 Hz), 7.60 (d, J= 7.5 Hz), 7.26 (s), 4.66 (s), 4.48 (s), 3.91 (d, J= 7.6 Hz), 3.59 (br s), 3.45 (br s), 2.11 (m), 0.95 (d, J= 6.6 Hz).13C NMR (125 MHz, CDCI3) 6 160.7, 151.4, 151.3, 146.7, 141.7, 139.9, 136.0, 135.8, 130.8, 129.2, 128.9, 128.9, 127.7, 124.4, 122.6, 122.0, 119.6, 116.6, 114.3, 57.8, 56.3, 51.8, 50.6, 50.5, 28.1, 19.6, 19.6. MS (ESI+): m / z = 442.4 [M + H]+.
[0619] Synthesis of 3-isobutyl-2-( 4-(pyrimidin-2-ylmethyl)piperazin-l-yl)methyl)quinazolin-4(3H)-one (ZLB14)
[0620]
[0621] ZLB14
[0622] N,N-Diisopropylethylamine (DIPEA) (728.7 mg, 5.64 mmol) was added to a solution of 2-(2-chloroethanamido)benzoic acid (1 g, 4.7 mmol) at room temperature (r.t.) in dioxane (0.2 M, 23.5 ml) and stirred for 2 minutes before the dropwise addition of phosphorous trichloride (222.2 mg, 5.64 mmol). After 10 minutes of stirring at r.t., 2-isobutylamine (308.8 mg, 4.23 mmol) was added dropwise as a 1.5 M solution (2.8 ml) in dioxane and the resulting mixture was heated to 70 °C and stirred for an additional 8 hours. The quinazolinone intermediate of 2-(chloromethyl)-3-isobutylquinazolin-4(3H)-one (Scheme 6, int-8) was generated and then purified by silica gel column chromatography and immediately used for the next step. Piperazine (516.8 mg, 6.00 mmol) was added to a solution of the quinazolinone intermediate int-8 (501.5 mg, 2.00 mmol) in tetrahydrofuran (THF) (0.2 M) and the resulting mixture was stirred at r.t. for 12 hours. The reaction mixture was then concentrated underAtorney Docket No. 090723-1556314-25-044PCT
[0623] reduced pressure. High performance liquid chromatography (HPLC) afforded the corresponding 3-isobutyl-2-(piperazin-l-ylmethyl)quinazolin-4(3H)-one (Scheme 6, int-9).
[0624] Pyrimidine-2-carbaldehyde (21.6 mg, 0.20 mmol), was added to piperazine quinazolinone int-9 (40.0 mg, 0.13 mmol) followed by sodium triacetoxyborohydride (42.3 mg, 0.20 mmol). The reaction was stirred at r.t. for 2 hours. The product was purified by HPLC chromatography (ACN / H2O with 0.1% TFA) to afford ZLB14 as a yellow gum (40.3 mg).
[0625] 'HNMR (500 MHz, CD3OD) 88.87 (d, J= 5.0 Hz), 8.24 (d, J= 8.2 Hz), 7.87 (dd, J = 8.1, 8.1 Hz), 7.82 (d, J= 8.1 Hz), 7.61 (dd, J= 8., 8.1 Hz), 7.50 (dd, J= 5.0 Hz), 4.64 (d, J = 2.4 Hz), 4.13 (d, J= 7.5 Hz), 3.63 (m), 3.57 (br s), 2.23 (m), 1.00 (d, J= 6.7 Hz).13C NMR (125 MHz, CD3OD) 6 163.4, 162.1, 159.2, 159.2, 154.2, 146.0, 136.2, 129.1, 127.9, 126.9, 122.3, 121.6, 61.4, 55.1, 53.0, 51.3, 51.1, 51.1, 29.5, 20.4, 20.4. MS (ESI+): m / z = 393.3 [M + H]+.
[0626] Synthesis of 3-(2-isopropoxyphenyl)-2-( 4-(pyrimidin-2-ylmethyl)piperazin-l-y I) me thy I) quinazolin-4 ( 3H) -one (ZLA 3 )
[0627]
[0628] ZLA3
[0629] N,N-Diisopropylethylamine (DIPEA) (363.0 mg, 2.8 mmol) was added to a solution of 2-(2-chloroethanamido)benzoic acid (500 mg, 2.3 mmol) at room temperature (r.t.) in dioxane (0.2 M, 23.5 ml) and stirred for 2 minutes before the dropwise addition of phosphorous trichloride (772.7 mg, 5.64 mmol). After 10 minutes of stirring at r.t., 2-isopropoxy aniline (308.8 mg, 4.23 mmol) was added dropwise as a 1.5 M solution (1.8 ml) in dioxane and the resulting mixture was heated to 70 °C and stirred for an additional 8 hours. The quinazolinone intermediate of 2-(chloromethyl)-3-(2-isopropoxyphenyl)quinazolin-4(3H)-one (Scheme 6, int-7) was purified by silica gel column chromatography and immediately used for the next step. Piperazine (314.4 mg, 3.6 mmol) was added to a solution of the quinazolinone intermediate int-7 (Scheme 6) (400.0 mg, 2.00 mmol) in tetrahydrofuran (THF) (1.2 M) andAtorney Docket No. 090723-1556314-25-044PCT
[0630] the resulting mixture was stirred at r.t. for 12 hours. The reaction mixture was then concentrated under reduced pressure. High performance liquid chromatography (HPLC) afforded the corresponding 3-(2-isopropoxyphenyl)-2-(piperazin-l-ylmethyl)quinazolin-4(3H)-one (int-10). 2-quinolinecarboxaldehyde (31.4 mg, 0.20 mmol), was added to piperazine quinazolinone int-10 (40.0 mg, 0.13 mmol) followed by sodium triacetoxyborohydride (42.3 mg, 0.20 mmol). The reaction was stirred at r.t. for 2 hours. The product was purified by HPLC (ACN / H2O with 0.1% TFA) to afford ZLA3 as yellow gum (40.3 mg).
[0631] ‘H NMR (500 MHz, CDCh) 6 8.89 (d, J= 8.2 Hz), 8.41 (d, J= 8.7 Hz), 8.27 (d, J = 7.9 Hz), 8.16 (d, J= 8.2 Hz), 8.11 (dd, J= 7.8, 7.8 Hz), 8.01 (d, J= 8.2 Hz), 7.92 (dd, J= 7.6, 7.6 Hz), 7.84 (dd, J= 7.6, 7.6 Hz), 7.76 (d, J= 8.2 Hz), 7.60 (d, J= 7.5 Hz), 7.26 (s), 4.66 (s), 4.48 (s), 3.91 (d, J= 7.6 Hz), 3.59 (br s), 3.45 (br s), 2.11 (m), 0.95 (d, J= 6.6 Hz).13C NMR (125 MHz, CDCh) 6 160.7, 151.4, 151.3, 146.7, 141.7, 139.9, 136.0, 135.8, 130.8, 129.2, 128.9, 128.9, 127.7, 124.4, 122.6, 122.0, 119.6, 116.6, 114.3, 57.8, 56.3, 51.8, 50.6, 50.5, 28.1, 19.6, 19.6. MS (ESI+): m!z = 471.4 [M + H]+.
[0632] Synthesis of 2-((4-(2-( lH-imidazol-l-yl)acetyl)piperazin-l-yl)methyl)-3-(2-isopropoxyphenyl) quinazolin-4 ( 3H) -one (ZLA21 )
[0633]
[0634] ZLA21
[0635] N,N-Diisopropylethylamine (DIPEA) (363.0 mg, 2.8 mmol) was added to a solution of 2-(2-chloroethanamido)benzoic acid (500 mg, 2.3 mmol) at room temperature (r.t.) in dioxane (0.2 M, 23.5 ml) and stirred for 2 minutes before the dropwise addition of phosphorous trichloride (772.7 mg, 5.64 mmol). After 10 minutes of stirring at r.t., 2-isopropoxy aniline (308.8 mg, 4.23 mmol) was added dropwise as a 1.5 M solution (1.8 ml) in dioxane and the resulting mixture was heated to 70 °C and stirred for an additional 8 hours. The quinazolinone intermediate int-7 (Scheme 6) was purified by silica gel column chromatography and immediately used for the next step. Piperazine (314.4 mg, 3.6 mmol) was added to a solutionAtorney Docket No. 090723-1556314-25-044PCT
[0636] of the quinazolinone intermediate int-7 (Scheme 6)(400.0 mg, 2.00 mmol) in tetrahydrofuran (THF) (1.2 M) and the resulting mixture was stirred at r.t. for 12 hours. The reaction mixture was then concentrated under reduced pressure. High performance liquid chromatography (HPLC) afforded the corresponding piperazine quinazolinone int-10. Then the piperazine quinazolinone int-10 was dissolved in dichloromethane (DCM) and ethyldiisopropylamine (EDIP A) (1.2 eq) was added at r.t.. The mixture was then cooled at 0 °C, followed by the addition of 2-(lH-imidazol-l-yl)acetyl chloride (1.2 eq) and 4-dimethylaminopyridine (4-DMAP) (0.5 eq). The reaction was slowly warmed to r.t. and stirred for 2 hours. The product was purified by HPLC (ACN / H2O with 0.1% TFA) to afford ZLA21 as a yellow gum.
[0637] 'H NMR (500 MHz, CD3OD) 8 8.90 (m), 8.26 (d, J= 8.3 Hz), 7.94 (dd, J= 8.3, 8.3 Hz), 7.91 (d, J= 8.3 Hz), 7.64 (dd, J= 8.3, 8.3 Hz), 7.58 (overlapped), 7.57 (overlapped), 7.54 (m), 7.41 (d, J= 7.8 Hz), 7.31 (d, J= 7.8 Hz), 7.18 (dd, J= 7.8, 7.8 Hz), 5.42 (s), 4.72 (m), 4.32 (d, J= 16.8 Hz), 4.00 (m), 3.97 (d, J= 16.8 Hz), 3.65 (m), 1.26 (d, J= 6.0 Hz) ), 1.13 (d, J = 6.0 Hz).13C NMR (125 MHz, CD3OD) 6 165.7, 162.9, 154.4, 149.0, 147.5, 138.1, 136.5, 133.2, 131.2, 129.3, 128.5, 128.0, 125.0, 124.9, 122.7, 120.4, 116.5, 72.7, 57.5, 53.8, 53.7, 50.9, 42.8, 40.4, 22.7, 21.8. MS (ESI+): m / z = 487.4 [M + H]+.
[0638] Synthesis of 2-((4-(3-cyclohexylpropanoyl)piperazin-l-yl)methyl)-3-(2-isopropoxyphenyl)quinazolin-4(3H)-one (ZLA22)
[0639]
[0640] N,N-Diisopropylethylamine (DIPEA) (363.0 mg, 2.8 mmol) was added to a solution of 2-(2-chloroethanamido)benzoic acid (500 mg, 2.3 mmol) at room temperature (r.t.) in dioxane (0.2 M, 23.5 ml) and stirred for 2 minutes before the dropwise addition of phosphorous trichloride (772.7 mg, 5.64 mmol). After 10 minutes of stirring at r.t., 2-isopropoxy aniline (308.8 mg, 4.23 mmol) was added dropwise as a 1.5 M solution (1.8 ml) in dioxane and the resulting mixture was heated to 70 °C and stirred for an additional 8 hours. The quinazolinoneAtorney Docket No. 090723-1556314-25-044PCT
[0641] intermediate int-7 (Scheme 6) was purified by silica gel column chromatography and immediately used for the next step. Piperazine (314.4 mg, 3.6 mmol) was added to a solution of the quinazolinone intermediate int-7 (Scheme 6) (400.0 mg, 2.00 mmol) in tetrahydrofuran (THF) (1.2 M) and the resulting mixture was stirred at r.t. for 12 hours. The reaction mixture was then concentrated under reduced pressure. High performance liquid chromatography (HPLC) afforded the corresponding piperazine quinazolinone int-10. Then the piperazine quinazolinone int-10 was dissolved in dichloromethane (DCM) and ethyldiisopropylamine (EDIP A) (1.2 eq) was added at r.t.. The mixture was then cooled at 0 °C, followed by addition of 3-cyclohexylpropanoyl chloride (1.2 eq) and 4-dimethylaminopyridine (4-DMAP) (0.5 eq). The reaction was slowly warmed to r.t. and stirred for 2 hours. The product was purified by HPLC (ACN / H2O with 0.1% TFA) to afford ZLA22 as a yellow gum.
[0642] 'H NMR (500 MHz, CD3OD) 88.25 (d, J= 8.3 Hz), 7.93 (dd, J= 8.3, 8.3 Hz), 7.88 (d, J= 8.3 Hz), 7.62 (d, J= 8.3 Hz), 7.57 (dd, J= 2.2, 2.2 Hz), 7.39 (d, J= 2.2 Hz), 7.29 (d, J = 2.2 Hz), 7.16 (dd, J= 2.2, 2.2 Hz), 4.71 (m), 4.34 (d, J= 16.8 Hz), 3.96 (d, J= 16.8 Hz), 3.96 (m), 3.50 (m), 2.44 (m), 1.73 (m), 1.67 (m), 1.28 (m), 1.26 (d,J= 6.0Hz), 1.20 (m), 1.13 (d, J = 6.0 Hz), 0.92 (m).13C NMR (125 MHz, CD3OD) 6 174.5, 162.8, 154.3, 148.8, 147.5, 136.4, 133.2, 131.1, 129.2, 128.5, 127.9, 124.9, 122.6, 122.2, 116.4, 72.7, 57.3, 54.1, 54.0, 49.5, 49.3, 49.2, 49.2, 49.0, 48.8, 48.7, 48.5, 43.5, 39.6, 38.6, 34.2, 34.2, 33.6, 31.2, 27.6, 27.3, 27.3, 22.7, 21.8. MS (ESI+): m / z = 517.5 [M + H]+.
[0643] 2-((4-(2-(4-chlorophenoxy)acetyl)piperazin-l-yl)methyl)-3-(2-isopropoxyphenyl)pyrido[2, 3-d]pyrimidin-4(3H)-one (ZLG1)
[0644]
[0645] Under an atmosphere of Argon, 2-aminonicotinic acid (1.1 g) was dissolved in 15 mL of DCM, Triethylamine (TEA) (1.2 mL, 1.1 eq) was then added, and the mixture was cooled in an ACN / dry ice bath (-40 °C). After 10 min stirring, a solution of chloroacetyl chlorideAtorney Docket No. 090723-1556314-25-044PCT
[0646] (629.0 uL, 1.1 eq) in DCM (2 mL) was added dropwise and the mixture allowed to stir for 8 hours at -40 °C. The reaction mixture was then filtered and extracted with DCM. After concentration under reduced pressure, pure compound int-11 (615.0 mg) was purified by preparative HPLC. DIPEA (67 uL, 1.2 eq) was added to a solution of int-11 (69 mg, 1.0 eq) at room temperature (r.t.) in dioxane (0.2 M, 1.5 ml) and stirred for 2 minutes before the dropwise addition of phosphorous trichloride (53.0 mg, 1.2 eq). After 10 minutes of stirring at r.t., 2-isopropoxy aniline (48.6 mg, 1.0 eq) was added dropwise as a 1.5 M solution in dioxane and the resulting mixture was heated to 70 °C and stirred for an additional 8 hours. The pyridopyrimidine intermediate int-12 (Scheme 6) was purified by silica gel column chromatography and immediately used for the next step. 2-(4-chl orophenoxy)-l -(piperazin- 1-yl)ethan-l-one (23.2 mg), KI (2 mg), and K2CO3 (16.8 mg) were added to a solution of the int-12 (Scheme 6) (20.0 mg) in tetrahydrofuran (THF) (1.2 M) and the resulting mixture was stirred at r.t. for 12 hours. The reaction mixture was then concentrated under reduced pressure. High performance liquid chromatography (HPLC) afforded the corresponding product ZLG1 as a light-yellow gum.
[0647] 'H NMR (500 MHz, CD3OD) 8 9.07 (dd, J= 4.7, 2.0 Hz), 8.73 (dd, J= 7.9, 2.0 Hz), 7.72 (dd, J= 7.9, 4.7 Hz), 7.62 (ddd, J= 8.5, 7.5, 1.7 Hz), 7.42 (dd, J= 7.8, 1.7 Hz), 7.32 (dd, J= 8.5, 1.1), 7.27 (m), 7.19 (m), 6.96 (m), 4.84 (s), 4.74 (m), 4.00 (m), 3.97 (m), 3.53 (m), 3.47 (m), 1.26 (d, J = 6.0 Hz), 1.14 (d, J = 6.0 Hz), FIG. HA.13C NMR (125 MHz, CD3OD) 6 167.3, 161.2, 156.7, 155.9, 155.9, 152.8, 152.4, 152.3, 137.4, 132.1, 129.6, 129.0, 126.2, 123.7, 123.0, 121.3, 116.9, 115.9, 115.0, 71.3, 66.2, 52.6, 41.7, 38.7, 21.3, 20.3, FIG. 11B. MS (ESI+): m!z= 548.4 [M + H]+.
[0648]
[0649] Under an atmosphere of Argon, 2-aminonicotinic acid (1.1 g) was dissolved in 15 mL of DCM, Triethylamine (TEA) (1.2 mL, 1.1 eq) was then added, and the mixture was cooledAtorney Docket No. 090723-1556314-25-044PCT
[0650] in an ACN / dry ice bath (-40 °C). After 10 min stirring, a solution of chloroacetyl chloride (629.0 uL, 1.1 eq) in DCM (2 mL) was added dropwise and the mixture allowed to stir for 8 hours at -40 °C. The reaction mixture was then filtered and extracted with DCM. After concentration under reduced pressure, pure compound int-11 (615.0 mg) was purified by preparative HPLC. DIPEA (32 uL, 1.2 eq) was added to a solution of int-11 (73.0 mg, 1.0 eq) at room temperature (r.t.) in dioxane (3.0 ml) and stirred for 2 minutes before the dropwise addition of phosphorous trichloride (56.1 mg, 1.2 eq). After 10 minutes of stirring at r.t., 4-fluoro-2-(propan-2-yloxy)aniline (57.6 mg, 1.0 eq) was added dropwise as a 1.5 M solution in dioxane and the resulting mixture was heated to 70 °C and stirred for an additional 8 hours. The pyridopyrimidine intermediate int-12 (Scheme 6) was purified by silica gel column chromatography and immediately used for the next step. 2-(4-chl orophenoxy)-l -(piperazin- 1-yl)ethan-l-one (54.2 mg), KI (3.5 mg), and K2CO3 (29.4 mg) were added to a solution of the int-12 (Scheme 6) (37.0 mg) in tetrahydrofuran (THF) (1.2 M) and the resulting mixture was stirred at r.t. for 12 hours. The reaction mixture was then concentrated under reduced pressure. High performance liquid chromatography (HPLC) afforded the corresponding product ZLG11 as a light-yellow gum.
[0651] ‘HNMR (600 MHz, DMSO-tL) 69.00 (br s), 8.61 (dd, J= 8.0, 2.0 Hz), 7.60 (m), 7.25 (m), 7.21 (m), 7.18 (m), 7.13 (m), 6.82 (m), 4.73 (s), 4.54 (m), 4.35 (m), 3.95 (m), 3.47 (m), 3.40 (m), 3.18 (m), 1.13 (d, J= 6.2 Hz), 0.98 (d, J= 6.2 Hz), FIG. 12A.13C NMR (150 MHz, DMSO-tfc) 6 168.7, 162.3, 158.8, 158.1, 157.2, 157.2, 157.1, 150.8, 138.9, 130.4, 127.6, 125.2, 124.8, 120.0, 119.8, 118.3, 118.3, 118.1, 117.8, 117.8, 117.3, 73.6, 67.6, 57.3, 54.0, 43.0, 40.0, 22.7, 21.7., FIG. 12B. MS (ESI+): m / z = 566.4 [M + H]+.
[0652]
[0653] Under an atmosphere of Argon, 2-aminonicotinic acid (1.1 g) was dissolved in 15 mL of DCM, Triethylamine (TEA) (1.2 mL, 1.1 eq) was then added, and the mixture was cooledAtorney Docket No. 090723-1556314-25-044PCT
[0654] in an ACN / dry ice bath (-40 °C). After 10 min stirring, a solution of chloroacetyl chloride (629.0 uL, 1.1 eq) in DCM (2 mL) was added dropwise and the mixture allowed to stir for 8 hours at -40 °C. The reaction mixture was then filtered and extracted with DCM. After concentration under reduced pressure, pure compound int-11 (615.0 mg) was purified by preparative HPLC. DIPEA (32 uL, 1.2 eq) was added to a solution of int-11 (33.0 mg, 1.0 eq) at room temperature (r.t.) in dioxane (3.0 ml) and stirred for 2 minutes before the dropwise addition of phosphorous trichloride (25.3 mg, 1.2 eq). After 10 minutes of stirring at r.t., 5-fluoro-2-(propan-2-yloxy)aniline (84.0 mg, 1.0 eq) was added dropwise as a 1.5 M solution in dioxane and the resulting mixture was heated to 70 °C and stirred for an additional 8 hours. The pyridopyrimidine intermediate int-12 (Scheme 6) was purified by silica gel column chromatography and immediately used for the next step. 2-(4-chl orophenoxy)-l -(piperazin- 1-yl)ethan-l-one (44.1 mg), KI (2.9 mg), and K2CO3 (23.9 mg) were added to a solution of the int-12 (Scheme 6) (30.0 mg) in tetrahydrofuran (THF) (1.2 M) and the resulting mixture was stirred at r.t. for 12 hours. The reaction mixture was then concentrated under reduced pressure. High performance liquid chromatography (HPLC) afforded the corresponding product ZLG12 as a light-yellow gum.
[0655] 'HNMR (600 MHz, CD3OD) 89.09 (d, J= 3.7 Hz), 8.73 (d, J= 7.8 Hz), 7.75 (dd, J = 7.9, 4.8 Hz), 7.39 (m), 7.35 (m), 7.31 (dd, J= 8.1, 2.9), 7.28 (m), 6.97 (m), 4.88 (s), 4.70 (m), 4.51 (d, J= 17.1 Hz), 4.10 (d, J= 17.1 Hz), 3.99 (br s), 3.60 (br s), 1.26 (d, J= 6.0 Hz), 1.12 (d, J= 6.0 Hz), FIG. 13A.13C NMR (150 MHz, CD3OD) 6 168.6, 162.6, 158.7, 158.1, 157.4, 157.4, 157.1, 150.8, 138.6, 130.4, 127.6, 125.4, 125.1, 119.6, 119.5, 118.4, 118.3, 117.6, 117.5, 117.3, 73.5, 67.6, 54.0, 53.9, 49.6, 43.7, 40.7, 40.4, 22.7, 21.7, FIG. 13B. MS (ESI+): m / z = 566.4 [M + H]+.
[0656]
[0657] Atorney Docket No. 090723-1556314-25-044PCT
[0658] Under an atmosphere of Argon, 2-aminonicotinic acid (1.1 g) was dissolved in 15 mL of DCM, Triethylamine (TEA) (1.2 mL, 1.1 eq) was then added, and the mixture was cooled in an ACN / dry ice bath (-40 °C). After 10 min stirring, a solution of chloroacetyl chloride (629.0 uL, 1.1 eq) in DCM (2 mL) was added dropwise and the mixture allowed to stir for 8 hours at -40 °C. The reaction mixture was then filtered and extracted with DCM. After concentration under reduced pressure, pure compound int-11 (615.0 mg) was purified by preparative HPLC. DIPEA (73 uL, 1.2 eq) was added to a solution of int-11 (75.0 mg, 1.0 eq) at room temperature (r.t.) in dioxane (3.0 ml) and stirred for 2 minutes before the dropwise addition of phosphorous trichloride (57.6 mg, 1.2 eq). After 10 minutes of stirring at r.t., 3-fluoro-2-isopropoxyaniline (59.1 mg, 1.0 eq) was added dropwise as a 1.5 M solution in dioxane and the resulting mixture was heated to 70 °C and stirred for an additional 8 hours. The pyridopyrimidine intermediate int-12 (Scheme 6) was purified by silica gel column chromatography and immediately used for the next step. 2-(4-chl orophenoxy)-l -(piperazin- 1-yl)ethan-l-one (54.2 mg), KI (3.5 mg), and K2CO3 (29.4 mg) were added to a solution of the int-12 (Scheme 6) (37.0 mg) in tetrahydrofuran (THF) (1.2 M) and the resulting mixture was stirred at r.t. for 12 hours. The reaction mixture was then concentrated under reduced pressure. High performance liquid chromatography (HPLC) afforded the corresponding product ZLG15 as a light-yellow gum.
[0659] 'H NMR (600 MHz, CD3OD) 8 9.09 (br s), 8.75 (dd, J= 7.9, 2.0 Hz), 7.74 (m), 7.46 (m), 7.32 (m), 7.31 (m), 7.26 (m), 6.95 (m), 4.86 (s), 4.59 (m), 4.36 (d, J= 17.1 Hz), 4.18 (d, J = 17.1 Hz), 3.98 (m), 3.55 (m), 1.23 (d, J= 6.0 Hz), 0.98 (d, J= 6.0 Hz), FIG. 14A.13C NMR (150 MHz, CD3OD) 6 168.7, 162.6, 158.1, 158.0, 157.1, 156.3, 153.3, 142.7, 142.6, 138.9, 130.4, 129.5, 129.5, 127.6, 126.9, 126.8, 125.4, 125.4, 120.8, 120.6, 118.3, 117.3, 78.8, 78.8, 67.6, 57.4, 54.0, 43.0, 40.0, 23.2, 22.5., FIG. 14B. MS (ESI+): m / z = 566.4 [M + H]+.
[0660]
[0661] Atorney Docket No. 090723-1556314-25-044PCT
[0662] Under an atmosphere of Argon, 2-aminonicotinic acid (1.1 g) was dissolved in 15 mL of DCM, Triethylamine (TEA) (1.2 mL, 1.1 eq) was then added, and the mixture was cooled in an ACN / dry ice bath (-40 °C). After 10 min stirring, a solution of chloroacetyl chloride (629.0 uL, 1.1 eq) in DCM (2 mL) was added dropwise and the mixture allowed to stir for 8 hours at -40 °C. The reaction mixture was then filtered and extracted with DCM. After concentration under reduced pressure, pure compound int-11 (615.0 mg) was purified by preparative HPLC. DIPEA (66 uL, 1.2 eq) was added to a solution of int-11 (68.0 mg, 1.0 eq) at room temperature (r.t.) in dioxane (3.0 ml) and stirred for 2 minutes before the dropwise addition of phosphorous trichloride (52.2 mg, 1.2 eq). After 10 minutes of stirring at r.t., 5-bromo-2-(propan-2-yloxy)aniline (72.9 mg, 1.0 eq) was added dropwise as a 1.5 M solution in dioxane and the resulting mixture was heated to 70 °C and stirred for an additional 8 hours. The bromo-pyridopyrimidine intermediate was purified by silica gel column chromatography and immediately used for the next step. 2-(4-chlorophenoxy)-l -(piperazin- l-yl)ethan-l -one (37.4 mg), KI (2.4 mg), and K2CO3 (20.3 mg) were added to a solution of the bromo-pyridopyrimidine intermediate (30.0 mg) in tetrahydrofuran (THF) (1.2 M) and the resulting mixture was stirred at r.t. for 12 hours. The reaction mixture was then concentrated under reduced pressure. High performance liquid chromatography (HPLC) afforded the bromoproduct as a light-yellow gum. A mixture of bromo-product (40.0 mg, 1 eq), Bis(pinacolato)diboron ELPi ) (81.0 mg, 5 eq), potassium acetate (AcOK) (25.1 mg, 4 eq), l,l'-Bis(diphenylphosphino)ferrocene]palladium(II) dichloride (Pd(dppf)C12) (4.7 mg, 0.1 eq) in 5 mL dioxane. Following, the mixture was stirred at 90 °C for 1 hour under N2 gas atmosphere. The crude reaction mixture was extracted with 300 mL ethyl acetate (EtOAc). The residue was chromatographed on HPLC (ACN) to afford ZLGB1 (20.8 mg) as a gum solid.
[0663] 'H NMR (600 MHz, CD3OD) 89.03 (br s), 8.68 (dd, J= 7.9, 1.9 Hz), 7.91 (dd, J= 8.4, 1.6 Hz), 7.79 (d, J= 1.6 Hz), 7.66 (dd, J= 8.0, 4.7 Hz), 7.27 (d, J= 8.4), 7.24 (m), 6.92 (m), 4.78 (s), 4.76 (m), 3.67 (m), 3.60 (m), 1.33 (s), 1.31 (s), 1.25 (d, J= 6.0 Hz), 1.16 (d, J= 6.0 Hz), FIG. 15A.13C NMR (150 MHz, CD3OD) 6 168.5, 163.4, 158.1, 157.9, 157.2, 156.7, 139.2, 138.4, 130.4, 127.4, 124.6, 117.3, 114.9, 85.3, 72.5, 67.7, 53.8, 53.7, 45.0, 42.0, 25.3, 25.3, 25.3, 25.2, 25.0, 22.7, 22.5, 21.9, FIG. 15B. MS (ESI+): mlz = 674.5 [M + H]+.
[0664] Example 10. Cell Viability Assay
[0665] The cell viability assays were evaluated using H520 cell line, Human colorectal adenocarcinoma cells and chemiluminescent reagents (CellTiter-Glo®, Promega Corporation, Madison, Wisconsin) in 96-well plate format according to the manufacturers protocol. CellsAtorney Docket No. 090723-1556314-25-044PCT
[0666] were exposed to 500 pM, 100 pM, 25 pM, 10 pM, 1 pM, or 0.5 pM compounds, DMSO and IKE (positive control), FIG. 16. Cells were incubated for a period of 48 h at 37 °C. Subsequently, CellTiter-Glo® reagent was added, and the plates were read using the High-Sensitivity Luminescence Hidex Sense Microplate Reader (Hidex, Turku, Finland) with standard settings. Each set of conditions was replicated at least three times. Error is reported as standard deviation (SD). Absolute ICso values are summarized in Table 4 below.
[0667] Table 4. Cell viability assay of compounds on the H520 cell line Compound IC50 (pM)
[0668] ZLB1 24.9
[0669] ZLB7 over 50
[0670] ZLB8 16.1
[0671] ZLB14 over 50
[0672] ZLA3 over 50
[0673]
[0674] IKE (positive control) 5.1
[0675] Example 11. [18F]FSPG uptake Assay
[0676] H460 cells were seeded on 24-well plates to yield approximately 105cells / well (500 pL) at the day of the uptake study. Cells were grown for 1.5 days under standard conditions (37 °C, 5% CO2). Cell culture medium was removed, and the cells were washed twice with phosphate-buffered saline (PBS). Radiotracers were added to the assay buffer (PBS / 0.1% w / v bovine serum albumin (BSA)) by using 5 pCi / well for [18F]-labeled FSPG. Cells were coincubated with competitors ZLB1, ZLB2, ZLB7, ZLB14, ZLA3, and ZL21 in excess at 1 mmol / L, for 60 minutes. Tracer uptake was stopped by the removal of the assay buffer. Cells were quickly washed three times with PBS and lysed by adding 1 N NaOH (0.5 mL). The cell lysate was removed from the plates and transferred to the tubes. The radioactivity of [18F]-samples was determined in a gamma counter as shown in FIG. 17. Data of [18F]FSPG uptake is summarized in Table 5, below, wherein the vehicle control is DMSO.
[0677] able 5. [18F]FSPG uptake assay of the compounds on H460 cells Compound [18F]FSPG uptake (%
[0678] compared with control)
[0679] Vehicle Control 100 %
[0680] IKE (positive control) 5.5 %
[0681] ZLB1 44.9 %
[0682] ZLB2 179.3 %
[0683] ZLB7 141.5 %
[0684] ZLB14 222.6 %
[0685] ZLA3 238.4 %
[0686]
[0687] ZLA21 200.1 %Atorney Docket No. 090723-1556314-25-044PCT
[0688] Example 12. [18F]FSPG uptake assay and [14C]cystine uptake assay on H460 cells [I8F]FSPG uptake assay: ZLG1, ZLG11, ZLG12, and ZLG15 as competitors
[0689] The H460 cell seeding on a 24-well plate yielded approximately 105cells / well (500 pL) at the day of the uptake study. Cells were grown for 1.5 days under standard conditions (37 °C, 5% CO2). Cell culture medium was removed, and the cells were washed twice with phosphate-buffered saline (PBS). Radiotracers were added to the assay buffer (PBS / 0.1% w / v bovine serum albumin (BSA)) by using 5 pCi / well for [18F]-labeled FSPG. Cells were coincubated with competitors at 10 pmol / L, for 60 minutes. Tracer uptake was stopped by the removal of the assay buffer. Cells were quickly washed three times with PBS and lysed by adding 1 N NaOH (0.5 mL). The cell lysate was removed from the plates and transferred to the tubes. The radioactivity of [18F]-samples was determined in a gamma counter. Data of [18F]FSPG uptake is summarized in Table 6, below. Compounds ZLG1-ZLG15 are shown as competitive inhibitors of [18F]FSPG accumulation in cancer cells, showing the cellular uptake percentage compared to the vehicle control (i.e., DMSO), FIG. 18A.
[0690] Table 6. [18F]FSPG uptake assay on H460 lung cancer cells Compound [18F]FSPG uptake (%
[0691] compared with control)
[0692] Vehicle Control 100 %
[0693] IKE (positive control) 50.1 %
[0694] ZLG1 49.2 %
[0695] ZLG11 43.8 %
[0696] ZLG12 45.2 %
[0697]
[0698] ZLG15 48.8%
[0699] [I4C]Cystine uptake assay: ZLG12 as competitor
[0700] H460 cells were seeded on a 96-well plate to yield approximately 2 *105cells / well (100 pL) at the day of the uptake study. Cells were grown for 1.5 days under standard conditions (37 °C, 5% CO2). Cell culture medium was removed, and the cells were washed twice with phosphate-buffered saline (PBS). Radiotracers were added to the Na+free assay buffer (137 mM Choline Chloride, 3 mM potassium chloride (KC1), 1 mM calcium chloride (CaCh), 1 mM magnesium chloride (MgCh), 5 mM D-Glucose, 0.7 mM dipotassium phosphate (K2HPO4), 10 mM HEPES (4-(2-hydroxyethyl)piperazine-l -ethane-sulfonic acid)) by using 0.012 pCi / well for [14C]cystine. Cells were co-incubated with competitors at different concentrations, for 60 minutes. Tracer uptake was stopped by the removal of the assay buffer. Cells were quickly washed three times with PBS and lysed by adding 0.1 N NaOH (50 pL). The cell lysate was removed from the plates and transferred to the tubes.Atorney Docket No. 090723-1556314-25-044PCT
[0701] Following, scintillation liquid 150 pL / well was added and the plate was sealed and incubated at room temperature for 2 hours to overnight before reading. The radioactivity of [14C]cystine was determined on a Hidex Sense Beta Plate Reader (Hindex, Turku, Finland). Compounds ZLG12 and IKE (positive control) are shown as competitive inhibitors of [14C]cystine accumulation in cancer cells, showing the ICso values of uptake percentage compared to the vehicle control, FIG. 18B.
[0702] Example 13. Synthesis of [18F]-labeled glutamate analogs as positron emission tomography radiotracers of cystine / glutamate antiporter xCT
[0703] A general schematic for the synthesis of [18F]-labeled glutamate analogs as positron emission tomography radiotracers of cystine / glutamate antiporter xCT can be found in Scheme 5.
[0704] Scheme 7. Synthesis of [18F]-labeled glutamate analogs as positron emission tomography radiotracers of cystine / glutamate antiporter xCT.
[0705]
[0706]
[0707] [18F]ZLF2
[0708] Reagents and conditions for each step of the reactions are as follows: (a) (Boc)2O, triethylamine (EtsN), di chloromethane (DCM), at room temperature (r.t.) for 10 hours; (b) mixture with lithium bis(trimethylsilyl)amide (1.0 M in tetrahydrofuran (THF)), 3-Fluoropropyl trifluoromethanesulfonate added dropwise and stirred for 5 hours at -78 °C; (c) DCM, trifluoroacetic acid (TFA) at room temperature for 2 hours; (d) [18F]HF, Sb20s, 220 °C for 20 minutes.Atorney Docket No. 090723-1556314-25-044PCT
[0709] Synthesis of (2S,4S)-2-amino-4-(3,3,3-trijluoropropyl)pentanedioic acid (ZLF2)
[0710]
[0711] A flame-dried flask with a magnetic stirrer bar was charged with dry dichloromethane (DCM) (100 mL) and L-glutamic acid di-tert-butyl ester (11.8 g, 40 mmol, 1 eq). Triethylamine (EtiN) (11 mL, 80 mmol, 2 equiv) and di -tert-butyl di carb onate (87.2 mg, 1 eq) were added to the mixture over 15 minutes. Each of the tri ethylamine and di -tert-butyl di carb onate was added with a syringe pump at 0 °C. The mixture was stirred at room temperature for 10 hours. The mixture was washed with sat. aq. Sodium carbonate (Na2CCh) (100 mL). The aqueous layer was separated twice with DCM (2 x 60 mL). The organic phases were dried and filtered over magnesium sulfate (MgSCU). The organic phases were concentrated to obtain the product di-tert-butyl (tert-butoxycarbonyl)-L-glutamate (Scheme 7, Int-1). Int-1 (463 mg, 1.29 mmol) was dissolved in tetrahydrofuran (THF) (7 mL) and added to lithium bis(trimethylsilyl)amide in THF (1.0 M, 3.10 mmol) dropwise at -78 °C. The mixture was stirred for another 15 minutes. l,l,l-Trifluoro-3 -iodopropane (578 mg, 2.58 mmol, 2 eq) was dissolved in THF (5 mL) and added dropwise to the mixture. The resulting mixture was stirred for 5 hours at -78 °C. Then ammonium chloride (NH4Q) (sat, 12.5 mL) was added, and the resulting mixture was treated with DCM (25 mL) and H2O (12.5 mL). The organic extract was washed with brine, dried over MgSCU, filtered, and evaporated. The product Int-5 (Scheme 7) was chromatographed on HPLC (ACN / H2O with 0.1% TFA). To a solution of Int-5 (17.3 mg) in DCM (300 pL) was added trifluoro acetic acid (TFA, 300 pL) dropwise. The mixture was stirred at room temperature for 1 hour and then evaporated. The residue was triturated with diethyl ether to afford ZLF2 (TFA salt, 5 mg, 57 %) as a white solid.
[0712] 1HNMR(600 MHz, DMSO-tL) 63.85 (m), 2.65 (m), 2.24 (m), 2.03 (m), 1.87 (m), 1.73 (m).13C NMR (150 MHz, DMSO-tfc) 6 174.8, 170.5, 130.7 (-CF3), 128.5 (-CF3), 126.3 (-CF3), 124.1 (-CF3), 50.1, 39.4, 31.8, 30.8 (-C*H2CF3), 30.6 (-C*H2CF3), 30.3 (-C*H2CF3), 30.1 (-C*H2CF3), 23.5. MS (ESI+): m / z = 244.1 [M + H]+.Atorney Docket No. 090723-1556314-25-044PCT
[0713] Example 14. In vitro assays of [18F]ZLF5, [18F]FSPG, [18F]ZLF16, [131I]ZLF7, and [131I]ZLF18 in Cancer Cells
[0714] General Procedure: Cancer cells were seeded in a 24-well plate and yielded approximately 105cells / well in 0.5 mL. Cells were allowed to grow for 2 days under standard conditions (37 °C, 5% CO2). Cell culture medium was removed, and the cells were washed twice with phosphate-buffered saline (PBS). The [18F]-labeled compound (4 pCi / well) or [131I]-labeled compound (0.5 pCi / well) was added with or without the corresponding “cold” compound (0.5 mM) to the cells in assay buffer and incubated at 37 °C for pre-determined time periods. For competition assay, cells were co-incubated with the radiotracer in the presence of 0.5 mM competitors for 60 minutes. Tracer uptake was stopped by the removal of the assay buffer and quickly washed three times with ice-cold PBS. To measure the amount of internalized and membrane-bound radioactivity, stripping buffer (0.1 M sodium acetate, pH 2-3) was added to the cells and incubated at room temperature for 15 min. The stripping buffer was collected and transferred to a gamma counting tube. The cells were lysed by adding 0.1 NNaOH. The cell lysate was transferred to a gamma counting tubes. The radioactivity of [18F]-samples was measured by a gamma counter (Lablogic Systems, UK).
[0715] FIG. 20A shows a graph of [18F]ZLF5 uptake as a percentage of total radioactivity per mg protein over a period of 4 hours in the absence and presence of cold ZLF5 in H460, A549, and H520 lung cancer cell lines.
[0716] FIG. 20B shows a graph of [18F]ZLF5 uptake as a percentage of total radioactivity per mg protein over a period of 4 hours in the absence and presence of cold ZLF5 in U251 and U87 glioblastoma cell lines.
[0717] FIG. 20C shows a graph of [18F]ZLF5 uptake as a percentage of total radioactivity per mg protein over a period of 4 hours in the absence and presence of cold ZLF5 in HCC-mHEL and HCC-Control cell lines.
[0718] FIG. 20D shows a graph of [18F]ZLF5 uptake as a percentage of total radioactivity per mg protein over a period of 4 hours in the absence and presence of cold ZLF5 in SW480, SW620, HT29, and HCT116 CRC cell lines.
[0719] FIG. 21 shows a graph of [18F]ZLF5 and [18F]F SPG uptake, respectively, as a percentage of total radioactivity per mg protein over a period of 4 hours in H460 cell lines.
[0720] FIG. 22A shows a graph of [18F]ZLF16 uptake as a percentage of total radioactivity per mg protein over a period of 4 hours in the absence and presence of cold ZLF16 in U251 and U87 cell lines.Atorney Docket No. 090723-1556314-25-044PCT
[0721] FIG. 22B shows a graph of [18F]ZLF16 uptake assay and competitor compounds ZLF16, FSPG, L-Cys, L-Glu, L-Gln, L-Asp, BCH, and IKE on glioblastoma cell lines.
[0722] FIG. 22C shows a graph of [18F]ZLF16 uptake as a percentage of total radioactivity per mg protein over a period of 1 hour in the absence and presence of cold ZLF16 in U251 and U87 cell lines.
[0723] FIG. 23A shows a graph of [131I]ZLF7 uptake as a percentage of total radioactivity per mg protein over a period of 4 hours in the absence and presence of cold ZLF7 in H460 and HT29 cell lines.
[0724] FIG. 23B shows a graph of [131I]ZLF18 uptake as a percentage of total radioactivity per mg protein over a period of 4 hours in the absence and presence of cold ZLF18 in H460 and HT29 cell lines.
[0725] FIG. 23C shows a graph of [131I]ZLF7 uptake assay and competitor compounds ZLF7, FSPG, L-Glu, L-Cys, L-Asp, IKE, and BCH on H460 cell lines.
[0726] Example 15. Biodistribution of [18F]ZLF5 and [18F]FSPG
[0727] C57BL / 6 mice were administered intravenously [18F]ZLF5 or [18F]FSPG (3.7 ± 0.37 MBq / mouse) through the tail vein. At 15, 30, 60, and 120 min post-injection, the mice were euthanized by CO2 inhalation. Blood, urine, feces and major organ tissues were harvested, weighed, and assessed for radioactivity. The amount of radioactivity was determined with a gamma counter (Lablogic, Systems, UK) to calculate uptake as the percentage of injected dose per gram of tissue (%ID / g), based on decay-corrected radioactivity values.
[0728] FIG. 24A shows a graph of the biodistribution of [18F]ZLF5 in C57BL / 6 mice. FIG.
[0729] 24B shows a graph of the biodistribution of [18F]FSPG in C57BL / 6 mice.
[0730] Example 16. PET / CT Imaging of [18F]ZLF16 in C57BL / 6 mice
[0731] Positron Emission Tomography / Computed Tomography (PET / CT) scans were performed using a Bruker Albira PET / CT preclinical imaging system (Billerica, MA). The mouse was anesthetized with isoflurane (2% in O2) and placed on the scanner in a prone position. [18F]ZLF16 (4.0 MBq / mouse) was injected intravenously to the tail vein through a catheter. PET acquisition started 3 seconds before injection and continued over 60 minutes, followed by 5 minutes CT. The mouse was maintained under anesthesia during all imaging procedures. Basic physiological functions including respiratory rate were monitored by Biopac system throughout the whole imaging procedures. The PET images were reconstructed using a maximum likelihood expectation-maximum algorithm. The CT imagesAtorney Docket No. 090723-1556314-25-044PCT
[0732] were reconstructed using a filtered back projection algorithm. The fusion of PET and CT images was performed using PMOD software version 4.0 (PMOD Technologies LLC, Zurich, Switzerland).
[0733] FIG. 25 shows a PET / CT image of [18F]ZLF16 in C57BL / 6 mice.
[0734] Example 17. In vivo data of [18F]ZLF16 in the preclinical glioma rat model U87MG.
[0735] Human glioblastoma tumors were established by orthotopic implantation of luciferase-transfected U87MG-Luc human glioblastoma cells into 5-week-old Wistar rats. Tumor growth was monitored longitudinally using IVIS bioluminescence imaging (BLI). In vivo magnetic resonance imaging (MRI) and positron emission tomography (PET) were performed once BLI signals from tumor regions exceeded an average of 1 x 107photons / sec. T2-weighted MRI was conducted using a 7-Tesla Bruker BioSpec preclinical MRI scanner. PET imaging was performed on a Bruker Albira PET / CT system with a 90-minute dynamic acquisition following tail vein administration of the radiotracer [18F]ZLF16 (1.0-1.3 mCi). After imaging, brains were harvested and sectioned using a cryostat to obtain 2 mm-thick slices for ex vivo autoradiography. The remaining brain tissues were immediately flash-frozen in Optimal Cutting Temperature (OCT) compound using 2-methylbutane pre-cooled with liquid nitrogen (-40 to -50 °C). Frozen tissues were then sectioned with a cryostat, mounted onto Superfrost Plus slides, and stored at -20 °C until further processing. Hematoxylin and eosin (H&E) staining of brain slice was performed to evaluate tissue morphology and confirm tumor localization. Subsequently, immunohistochemical (IHC) staining was carried out to assess xCT and Ki-67 (a nuclear protein expressed in actively dividing cells, serving as a key marker of cell proliferation and tumor aggressiveness) expression.
[0736] In pilot in vivo studies, the PET tracer, [18F]ZLF16, exhibited excellent healthy brain penetrance with rapid wash out from non-tumor tissue; in contrast, experimental U87MG gliomas model, even with low levels of xCT, exhibited enhanced accumulation and retention (FIG. 26A-C). Ex vivo, strong agreement was observed between radiotracer accumulation, xCT, and Ki67 immunoreactivity (FIG.26D-G).
[0737] The compounds and methods of the appended claims are not limited in scope by the specific compounds and methods described herein, which are intended as illustrations of a few aspects of the claims and any compounds and methods that are functionally equivalent are within the scope of this disclosure. Various modifications of the compounds and methods in addition to those shown and described herein are intended to fall within the scope of theAttorney Docket No. 090723-1556314-25-044PCT
[0738] appended claims. Further, while only certain representative compounds, methods, and aspects of these compounds and methods are specifically described, other compounds and methods are intended to fall within the scope of the appended claims. Thus, a combination of steps, elements, components, or constituents can be explicitly mentioned herein; however, all other combinations of steps, elements, components, and constituents are included, even though not explicitly stated.
Claims
Attorney Docket No. 090723-1556314-25-044PCTWHAT IS CLAIMED IS:A compound of Formula (I):O O(I)or stereoisomers, salts, and prodrugs thereof, wherein:n is 1, 2, 3 or 4; andQ is -(CH2)R or -CR1R2R3, wherein,R is a substituted aryl; andRi, R2, and R3 are each independently hydrogen, halogen, or halogen isotope.
2. The compound of claim 1, wherein n is 2 or 3.
3. The compound of claim 1 or claim 2, wherein the substituted aryl is a substituted phenyl.
4. The compound of claim 3, wherein the substituted phenyl is:wherein:Y is a halogen or halogen isotope; andm is 1, 2, or 3.The compound of claim 4, wherein the substituted phenyl is:The compound of claim 5, wherein the substituted phenyl is:Atorney Docket No. 090723-1556314-25-044PCTwherein Y is a halogen or halogen isotope.
7. The compound of claim 1, wherein Ri, R2, and R3 are each independently halogen or halogen isotope.
8. The compound of claim 1 or claim 7, wherein at least one of Ri, R2, and R3 is halogen isotope.
9. The compound of claim 1 or claim 7, wherein at least one of Ri, R2, and R3 is halogen.
10. The compound of claim 1 or claim 7, wherein at least two of Ri, R2, and R3, are halogen.
11. The compound of any one of claims 1 to 10, wherein the halogen isotope is [18F], [77Br], [76Br], [123I], [124I], [125I], [131I], or [211At],12. The compound of claim 11, wherein the halogen isotope is [18F],13. The compound of any one of claims 1 to 10, wherein the halogen is F, I, Br, or At.
14. The compound of claim 13, wherein the halogen is F.
15. A compound of Formula (la):HO OH(Y)m(la)Attorney Docket No. 090723-1556314-25-044PCTor stereoisomers, salts, and prodrugs thereof, wherein:Y is a halogen or halogen isotope; andm is 1, 2, or 3.
16. The compound of claim 15, wherein m is 1.
17. The compound of claim 15, wherein m is 2 or 3.
18. The compound of claim 17, wherein when m is 2 or 3, one Y is halogen isotope.
19. The compound of any one of claims 15 to 18, wherein the halogen isotope is [18F], [77Br], [76Br], [123I], [124I], [125I], [131I], or [211At]20. The compound of any one of claims 15 to 18, wherein the halogen is F, I, Br, or At.
21. The compound of claim 15, wherein the compound is:[123I]ZLF6Attorney Docket No. 090723-1556314-25-044PCTZLF7[At]ZLF8ZLF12 ZLF11O OZLF13 ZLF14Attorney Docket No. 090723-1556314-25-044PCTor stereoisomers, salts, and prodrugs thereof.
22. The compound of claim 21, wherein the compound is:or stereoisomers, salts, and prodrugs thereof.
23. A compound of Formula (lb) or Formula (lb’):Attorney Docket No. 090723-1556314-25-044PCTor stereoisomers, salts, and prodrugs thereof, wherein:Y is a halogen or halogen isotope; andm is 1, 2, or 3.
24. The compound of claim 23, wherein the halogen isotope is [18F], [77Br], [ ’Br], [123I], [124I], [125I], [131I], or [211At],25. The compound of claim 23, wherein the halogen is F, I, Br, or At.
26. The compound of claim 23, wherein the compound is:ZLF16Attorney Docket No. 090723-1556314-25-044PCTor stereoisomers, salts, and prodrugs thereof.
27. A compound of the following formula:or stereoisomers, salts, and prodrugs thereof.
28. A compound of Formula (II):oAR2 (II)or stereoisomers, salts, and prodrugs thereof, wherein:X is -N- or -CH-;Ri is selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted heteroalkenyl, substituted or unsubstituted heteroalkynyl, substituted or unsubstituted haloalkyl, substituted or unsubstituted haloalkenyl, substituted or unsubstituted haloalkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl, and substituted or unsubstituted heterocycloalkyl; andR2 is selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted heteroalkenyl, substituted or unsubstituted heteroalkynyl, substituted or unsubstituted haloalkyl, substituted or unsubstituted haloalkenyl, substituted or unsubstituted haloalkynyl, substituted and unsubstituted carbonyl, substituted or unsubstituted carboxyl, substituted or unsubstitutedAttorney Docket No. 090723-1556314-25-044PCTaryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl, and substituted or unsubstituted heterocycloalkyl,Vwherein when Xis -CH- and Ri is , R2 is not29. The compound of claim 28, wherein X is -N-.
30. The compound of claim 28, wherein X is -CH-.
31. The compound of any one of claims 28 to 30, wherein Ri isorwherein:n is 0, 1, 2, 3, or 4; andRi’ is halogen or bis(pinacolato)diboron.
32. The compound of claim 31, wherein when Ri is n is 0 or 1.
33. The compound of claim 32, wherein when n is 1, Rr is halogen.
34. The compound of claim 32, wherein when n is 1, Rr is bis(pinacolato)diboron.
35. The compound of any one of claims 28 to 34, wherein R2 isAttorney Docket No. 090723-1556314-25-044PCT 36. The compound of claim 28, wherein the compound is:ZLB7 ZLA3Atorney Docket No. 090723-1556314-25-044PCTAttorney Docket No. 090723-1556314-25-044PCTor stereoisomers, salts, and prodrugs thereof.
37. The compound of claim 36, wherein the compound is:Attorney Docket No. 090723-1556314-25-044PCTor stereoisomers, salts, and prodrugs thereof.
38. A composition comprising a compound of any one of claims 1 to 37, and a carrier.
39. A pharmaceutical formulation comprising a compound of any one of claims 1 to 37 or a pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable excipient or carrier.
40. A kit comprising a compound of any one of claims 1 to 37, a composition of claim 38, or a pharmaceutical formulation of claim 39.
41. A composition comprising a compound of any one of claims 1 to 26, and a carrier.
42. A pharmaceutical formulation comprising a compound of any one of claims 1 to 26 or a pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable excipient or carrier.
43. A kit comprising a compound of any one of claims 1 to 26, a composition of claim 41, or a pharmaceutical formulation of claim 42.
44. A method for inhibiting cystine / glutamate antiporter xCT, comprising:administering an effective amount of a compound of any one of claims 1 to 37, a composition of claim 38, or a pharmaceutical formulation of claim 39.Attorney Docket No. 090723-1556314-25-044PCT45. The method of claim 44, wherein the compound inhibits xCT-mediated cystine / glutamate transport in a cell.
46. A method for treating or preventing a disease or condition associated with xCT-mediated cystine-glutamate transport, the method comprising:administering an effective amount of a compound of any one of claims 1 to 37, a composition of claim 38, or a pharmaceutical formulation of claim 39.
47. The method of claim 46, wherein the disease or condition associated with xCT-mediated cystine-glutamate transport is cancer.
48. The method of claim 47, wherein the cancer is liver cancer.
49. A method for diagnosing and treating a disease or condition associated with xCT expression in a subject, comprising:administering an effective amount of a compound of any one of claims 1 to 26, a composition of claim 41, or a pharmaceutical formulation of claim 42.
50. The method of claim 49, wherein the disease or condition associated with xCT expression in a subject is cancer.
51. The method of claim 50, wherein the cancer is liver cancer.
52. A method for imaging or killing cancerous cells in a subject, comprising:administering an effective amount of a radiotracer selected from Formula (la) or Formula (lb):O O 0 0Attorney Docket No. 090723-1556314-25-044PCTor stereoisomers or salts thereof, wherein:Y is a halogen or halogen isotope; andm is 1, 2 or 3, wherein when m is 1, Y is halogen isotope, and when m is 2 or 3, at least one Y is halogen isotope; andimaging the radiotracer using an imaging system.
53. The method of claim 52, wherein the halogen isotope is [18F], [77Br], [76Br], [123I], [124I], [125I], [131I], or [211At],54. The method of claim 52, wherein the halogen is F, I, Br, or At.
55. The method of claim 52 or claim 53, wherein the radiotracer is:[123I]ZLF6O O[211At]ZLF8 or stereoisomers or salts thereof.
56. The method of claim 52, wherein the imaging system is single photon emission computed tomography (SPECT) or positron emission tomography (PET).
57. The method of claim 56, wherein the imaging system is PET.Attorney Docket No. 090723-1556314-25-044PCT58. A method for imaging or killing cancerous cells in a subject, comprising:administering an effective amount of a radiotracer of the following formula:O O[18F]ZLF2or stereoisomers or salts thereof; andimaging the radiotracer using an imaging system.
59. The method of claim 58, wherein the imaging system is single photon emission computed tomography (SPECT) or positron emission tomography (PET).
60. The method of claim 59, wherein the imaging system is PET.
61. A compound of Formula (Ic) or Formula (Id):or stereoisomers or salts thereof, wherein:Z is a pinacol boronic ester, optionally Bpin, a boronic acid, optionally B(OH)2, or a trialkylstannyl group, optionally BusSn; andRi and R2 are each independently selected from hydrogen, acetyl, propanoyl, dimethylcarbamoyl, carbamoyl, carboxylic acid, ethoxy, diethylamino, acetate, and ethylthio.Attorney Docket No. 090723-1556314-25-044PCTor stereoisomers, salts, and prodrugs thereof.
62. A compound of the following formula:ZLFB3,ZLFB5,Attorney Docket No. 090723-1556314-25-044PCTZLFB2,ZLFB6,or stereoisomers, salts, and prodrugs thereof.
63. A compound of Formula (le) or Formula (If):or stereoisomers or salts thereof, wherein:Y is a halogen or halogen isotope;Attorney Docket No. 090723-1556314-25-044PCTm is 1, 2 or 3, wherein when m is 1, Y is halogen isotope, and when m is 2 or 3, at least one Y is halogen isotope; andRi and R2 are each independently selected from hydrogen, acetyl, propanoyl, dimethylcarbamoyl, carbamoyl, carboxylic acid, ethoxy, diethylamino, acetate, and ethylthio.
64. The compound of claim 63, wherein Ri and R2 are ortho- to the Y group.
